Novel methods for identifying HERV-derived epitopes
Through computer steps to identify HERVs associated with cancer and screen shared T cell epitopes, the problem of difficult to identify HERV-derived antigens shared among multiple cancer subtypes in the prior art is solved, and the therapeutic potential of multiple cancer types is improved .
Patent Information
- Application Number
- CN202380028778.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-25
- Filing Date
- 2023-01-25
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art is difficult to effectively identify HERV-derived antigens shared among multiple cancer subtypes, which limits the development of spot-based therapies for solid tumors.
A method that relies on selection steps was developed to identify cancer-associated HERVs through computer steps and select consensus T cell epitopes associated with cytotoxic T cell responses, evaluate the expression of these epitopes in tumor samples, and screen them out The most likely immunogenic HERV-derived epitope.
Selecting a limited number of tumor cell-specific overexpressing and immunogenic HERV-derived T cell epitopes among a large number of HERV candidates improves therapeutic potential in a variety of cancer types and provides new ways to prevent or treat cancer .
Smart Images

Figure CN119032273A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a method for identifying a HERV-derived T cell epitope associated with cancer, a peptide comprising an epitope identified by the method or consisting of an epitope identified by the method, an expression vector encoding the peptide, a cytotoxic T lymphocyte (CTL) of a subject treated with the peptide or vector, and an engineered T cell expressing a T cell receptor that recognizes the peptide. The present invention also relates to the use of the peptide, expression vector, CTL or engineered T cell as a vaccine or drug, in particular the use of the peptide, expression vector, CTL or engineered T cell for preventing or treating cancer in a subject in need thereof. Background Art
[0002] Adaptive T cell immune responses in cancer rely on the recognition of tumor epitopes specifically expressed by tumor cells. The role of neoantigens generated by non-synonymous mutations specific to the tumor genome has been extensively studied over the past decade, and many clinical trials have been launched to test neoantigen combinations in personalized cancer vaccines, with encouraging initial results. However, it remains challenging to determine the optimal neoepitope combination for each patient. In addition, there are many tumors characterized by low or moderate tumor mutation burden. Therefore, revealing other tumor antigen families that may be shared between different cancer subtypes, such as those derived from splice variants, fusion proteins, or endogenous reverse transcription factors, is crucial for the development of off-the-shelf therapies for solid tumors.
[0003] Human endogenous retroviruses (HERVs) account for 8% of the human genome. Although most HERV genes are non-functional due to DNA recombination, mutation and deletion, some HERV genes produce functional proteins, including group-specific antigens (Gag), polymerases (Pol) with reverse transcriptase, and envelope (Env) surface units. Most HERVs are inhibited by epigenetic mechanisms in normal cells. However, it has been reported that HERVs may become pathogenic substances by participating in insertional mutagenesis, chromosomal aberrations or LTR-induced oncogene activation. Therefore, HERVs may be an interesting source of shared tumor antigens.
[0004] In the prior art, patent application WO2020 / 049169 describes a method for identifying epitopes derived from HERVs and capable of eliciting specific CD8+ T cell responses. However, the method developed in this patent application is applied to a single cancer type, triple-negative breast cancer (TNBC), which has a limited number of HERVs. Therefore, there is still a need to develop new methods to identify HERV-derived antigens that effectively induce CD8+ T cell responses and are common in multiple cancer subtypes.
[0005] In this application, the inventors have developed a new method to meet this need. Specifically, the inventors have developed a method that relies on a selection step that can identify a limited number of epitopes that are effective among a large number of HERV candidates and shared by multiple cancer subtypes. SUMMARY OF THE INVENTION
[0007] The present invention relates to a method for identifying human endogenous retrovirus (HERV)-derived T-cell epitopes associated with at least one cancer, wherein the method comprises the following steps:
[0008] (a) identifying a HERV associated with at least one cancer, and
[0009] (b) selecting T cell epitopes in the HERV identified in the previous step, and
[0010] The method further comprises at least one, preferably two, of the following steps:
[0011] (i) selecting a HERV associated with a cytotoxic T cell response from among the cancer-associated HERVs identified in step (a), said step being between step (a) and step (b), and / or
[0012] (ii) evaluating the expression of the HERV-derived T-cell epitope identified in step (b) at the protein or peptide level in the tumor sample, said step being subsequent to step (b).
[0013] In one embodiment, steps (a) and (b) and steps (i) and / or (ii) are in silico steps. In one embodiment, step (ii) is an in vitro step.
[0014] The present invention relates to a computer method for identifying human endogenous retrovirus (HERV)-derived T-cell epitopes associated with cancer, wherein the method comprises the following steps:
[0015] (a) identifying and selecting HERVs associated with cancer, and
[0016] (b) selecting a common T cell epitope among the HERVs identified in the previous step, and
[0017] The method further comprises at least one, preferably two, of the following steps:
[0018] (i) selecting a HERV associated with a cytotoxic T cell response from among the cancer-associated HERVs identified in step (a), said step being between step (a) and step (b), and / or
[0019] (ii) evaluating the expression of the HERV-derived T-cell epitope identified in step (b) at the protein or peptide level in the tumor sample, said step being subsequent to step (b).
[0020] The present invention relates to a computer method for identifying human endogenous retrovirus (HERV)-derived T-cell epitopes associated with cancer, preferably associated with at least one cancer, wherein the method comprises the following steps:
[0021] (a) identifying HERVs associated with cancer, preferably associated with at least one cancer, and
[0022] (b) selecting T cell epitopes in the HERV identified in the previous step, and
[0023] The method further comprises at least one, preferably two, of the following steps:
[0024] (i) selecting a HERV associated with a cytotoxic T cell response from among the cancer-associated HERVs identified in step (a), said step being between step (a) and step (b), and / or
[0025] (ii) evaluating the expression of the HERV-derived T-cell epitope identified in step (b) at the protein or peptide level in the tumor sample, said step being subsequent to step (b).
[0026] In one embodiment, step (a) comprises the step of comparing HERV expression in tumor and normal samples.
[0027] In one embodiment, step (b) comprises the step of aligning the sequence of the HERV identified in the previous step with the HERV protein.
[0028] In one embodiment, step (b) further comprises the step of predicting binding of sequences having at least 70, 75, 80, 85, 90, 95, 96, 97, 98, 99% or more identity to a HERV protein to an MHC class I molecule.
[0029] In one embodiment, the association of the cancer-associated HERVs with the cytotoxic T cell response in step (i) is assessed by the association of each HERV with at least one CD4 or CD8 T cell signature, the association of each HERV with the functional signature is an interferon (IFN)-γ signature or cytolytic activity, and the lack of expression of each HERV in normal purified T cells or NK cells, preferably, the association is assessed by a machine learning-based method.
[0030] In one embodiment, the method further comprises, after step (b) or before step (ii), a step of selecting epitopes from the epitopes with the highest commonality among the cancer-associated HERVs identified in step (a).
[0031] In one embodiment, the method further comprises, after step (b) or after step (ii), a step of aligning the HERV-derived T-cell epitopes with the human proteome.
[0032] The present invention also relates to a peptide comprising or consisting of an epitope identified by the aforementioned method.
[0033] The present invention also relates to a peptide comprising or consisting of an epitope having a sequence selected from the group comprising or consisting of: RMLTDLRAV (SEQ ID NO: 3), LMAQAITGV (SEQ ID NO: 11), VLQDFDQPI (SEQ ID NO: 13), ALMIVSMVV (SEQ ID NO: 14), MLLAALMIV (SEQ ID NO: 15) and YIDDILCAA (SEQ ID NO: 16). The present invention also relates to a peptide comprising or consisting of a sequence selected from the group comprising or consisting of: RMLTDLRAV (SEQ ID NO: 3), LMAQAITGV (SEQ ID NO: 11), VLQDFDQPI (SEQ ID NO: 13), ALMIVSMVV (SEQ ID NO: 14), MLLAALMIV (SEQ ID NO: 15) and YIDDILCAA (SEQ ID NO: 16).
[0034] The present invention also relates to a peptide comprising or consisting of an epitope having a sequence selected from the group comprising or consisting of: RMLTDLRAV (SEQ ID NO: 3), LMAQAITGV (SEQ ID NO: 11), VLQDFDQPI (SEQ ID NO: 13), MLLAALMIV (SEQ ID NO: 15) and YIDDILCAA (SEQ ID NO: 16). The present invention also relates to a peptide comprising or consisting of a sequence selected from the group comprising or consisting of: RMLTDLRAV (SEQ ID NO: 3), LMAQAITGV (SEQ ID NO: 11), VLQDFDQPI (SEQ ID NO: 13), MLLAALMIV (SEQ ID NO: 15) and YIDDILCAA (SEQ ID NO: 16).
[0035] The present invention also relates to expression vectors that induce the expression of one or more of the above-mentioned peptides.
[0036] The present invention also relates to cytotoxic T lymphocytes of a subject treated with one or more peptides, or one or more expression vectors as described above.
[0037] The present invention also relates to engineered T cells expressing T cell receptors that recognize the above peptides.
[0038] The present invention also relates to one or more peptides, one or more expression vectors, one or more cytotoxic T lymphocytes, or one or more engineered T cells as described above, for use as a vaccine or a drug.
[0039] The present invention also relates to one or more peptides, one or more expression vectors, one or more cytotoxic T lymphocytes, or one or more engineered T cells as described above for use in preventing or treating cancer in a subject in need thereof.
[0040] In one embodiment, the cancer is selected from the group comprising or consisting of breast cancer (including triple negative breast cancer), ovarian cancer, melanoma, sarcoma, teratocarcinoma, bladder cancer, lung cancer (including non-small cell lung cancer and small cell lung cancer), head and neck cancer, colorectal cancer, glioblastoma, leukemia, lymphoma and other solid tumors and hematological malignancies.
[0041] definition
[0042] In the present invention, the following terms have the following meanings:
[0043] "Epitope" refers to the portion of an antigen that is capable of stimulating an immune response.
[0044] "Human endogenous retrovirus (HERV)" refers to a retrovirus that has integrated into germ cells and lost its ability to infect but retained its ability to transpose.
[0045] "Peptide" refers to a linear amino acid polymer of at least two amino acids linked together by peptide bonds. The amino acid residues in a peptide are abbreviated as follows: Phe or F for phenylalanine; Leu or L for leucine; Ile or I for isoleucine; Met or M for methionine; Val or V for valine; Ser or S for serine; Pro or P for proline; Thr or T for threonine; Ala or A for alanine; Tyr or Y for tyrosine; His or H for histidine; Gln or Q for glutamine; Asn or N for asparagine; Lys or K for lysine; Asp or D for aspartic acid; Glu or E for glutamic acid; Cys or C for cysteine; Trp or W for tryptophan; Arg or R for arginine; Gly or G for glycine.
[0046] "Prevention," "preventing," and "preventing" refer to preventative and prophylactic measures, the purpose of which is to reduce the probability of a subject developing a pathological condition or disorder within a given period of time. This reduction can be reflected, for example, in a delayed onset of at least one symptom of a pathological condition or disorder in a subject.
[0047] "Protective immune response" refers to the response of cytotoxic T lymphocytes (CTL) and / or helper T lymphocytes (HTL) to antigens derived from infectious agents or tumor antigens, which can prevent or at least partially arrest disease symptoms or progression. The immune response may also include antibody responses promoted by the stimulation of helper T cells.
[0048] "Subject" refers to a mammal, preferably a human. In one embodiment, the subject can be a "patient", i.e., a warm-blooded animal, more preferably a human, who is awaiting medical care or is receiving medical care or was / is / will be the subject of a medical procedure, or is being monitored for the development of a disease. The term "mammal" herein refers to any mammal, including humans, domestic and farm animals, and zoo animals, sports animals or pet animals, such as dogs, cats, cows, horses, sheep, pigs, goats, rabbits, etc. Preferably, the mammal is a primate, more preferably a human.
[0049] "Therapeutically effective amount" refers to a level or amount of one or more peptides, one or more expression vectors, one or more CTLs, or one or more engineered T cells described herein, which is intended to (1) delay or prevent the onset of a disease, disorder, or condition; (2) slow or stop the progression, aggravation, or worsening of one or more symptoms of a disease, disorder, or condition; (3) ameliorate the symptoms of a disease, disorder, or condition; (4) reduce the severity or incidence of a disease, disorder, or condition; or (5) cure a disease, disorder, or condition, without causing significant negative or adverse side effects to the target. A therapeutically effective amount may be administered before the onset of a disease, disorder, or condition for a prophylactic or preventive effect. Alternatively or additionally, a therapeutically effective amount may be administered after the onset of a disease, disorder, or condition for a therapeutic effect.
[0050] "Treatment" or "relief" refers to therapeutic treatment; its purpose is to slow down (mitigate) the target pathological condition or disorder. If, after receiving a therapeutic amount of one or more peptides, one or more expression vectors, one or more cytotoxic T lymphocytes, or one or more engineered T cells of the present invention, the patient shows an observable and / or measurable reduction or absence of one or more of the following parameters, the subject or mammal is successfully "treated" for cancer: the number of cancer cells (or tumor size) is reduced; the percentage of cancerous cells to total cells is reduced; and / or one or more symptoms associated with a particular disease or condition are alleviated to some extent; morbidity and mortality are reduced, and quality of life issues are improved. The above parameters for assessing successful treatment and improvement of the disease can be easily measured by routine procedures familiar to doctors.
[0051] A "vaccine" is a compound that, when administered to a patient, induces a humoral and / or cellular immune response that is protective.
[0052] "Vector" or "expression vector" refers to a vehicle for introducing DNA or RNA sequences (eg, foreign genes) into host cells to transform the host and promote the expression (eg, transcription and translation) of the introduced sequences. DETAILED DESCRIPTION OF THE INVENTION
[0054] The present invention relates to a method for identifying human endogenous retrovirus (HERV)-derived T-cell epitopes associated with cancer, preferably associated with at least one cancer.
[0055] In one embodiment, all steps of the method are performed in a computer, and the method of the present invention is a computer method.
[0056] The method of the present invention is particularly capable of selecting a limited number of HERV-derived T-cell epitopes that are specifically overexpressed by tumor cells and are most likely to be immunogenic among a large number of HERV candidates.
[0057] In one embodiment, the method can select a common epitope, i.e., an epitope shared among multiple patients suffering from the same cancer, and / or an epitope shared between different cancer types and / or an epitope shared between cancer-associated HERVs. In one embodiment, the epitope identified by the method of the present invention is shared by multiple patients suffering from the same cancer. In one embodiment, the epitope identified by the method of the present invention is shared between different cancer types. In one embodiment, the epitope identified by the method of the present invention is shared between cancer-associated HERVs.
[0058] In one embodiment, the method comprises at least 2, 3, 4, 5 or more of the following steps.
[0059] In one embodiment, the above method comprises the step of identifying HERV in tumor and normal samples. The HERV can be identified using a HERV database.
[0060] Methods for identifying HERV in a sample are well known to those skilled in the art, including but not limited to the use of reference tools such as Hervquant (CC Smith, et al., Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. Journal of Clinical Investigation. 128, 4804-4820 (2018)) or Telescope (Bendall et al., Telescope: Characterization of the retrotranscriptome by accurate estimation of transposable element expression, PLoS Comput Biol. 2019 Sep 30; 15 (9): e1006453).
[0061] In addition, HERV databases are described in the literature, see for example LVargiu et al., Classification and characterization of human endogenous retroviruses; mosaic forms are common. Retrovirology. 13, 7 (2016). HERV databases can also be derived from the Genbank database.
[0062] In one embodiment, a normal sample refers to a sample obtained from a subject not affected by cancer or refers to a sample obtained from a peritumoral location of a subject affected by cancer.
[0063] In one embodiment, a tumor sample refers to a sample of tumor tissue from a subject affected by cancer.
[0064] In one embodiment, the above method comprises the step of selecting HERVs associated with cancer, preferably HERVs associated with at least one cancer. This step can in particular select HERVs that are differentially expressed in tumor and normal samples.
[0065] In one embodiment, selecting a HERV associated with cancer comprises a step of comparing the expression of the HERV in tumor and normal samples. The comparison can be performed at the RNA level, which means comparing the RNA sequence expression of each HERV between tumor and normal samples.
[0066] The RNA sequence can be obtained from an RNA sequencing database and / or by extraction from fresh tissue.
[0067] In one embodiment, if the expression of the HERV in a tumor sample is 2, 2.5, 3, 3.5, 4, 4.5, 5 times or more higher than the expression in a normal sample, the HERV is associated with cancer, preferably associated with at least one cancer. In one embodiment, if the expression of the HERV in a tumor sample is 2 times higher than the expression in a normal sample, and the expression in any normal tissue is no more than 2 times compared to the expression in its matched tumor, the HERV is associated with cancer, preferably associated with at least one cancer.
[0068] In one embodiment, the above method comprises the step of selecting a HERV associated with a cytotoxic T cell response. This step can in particular select a HERV capable of inducing an immune response.
[0069] In one embodiment, the association of HERVs with a cytotoxic T cell response is assessed by phenotypic criteria. In one embodiment, the association of HERVs with a cytotoxic T cell response is assessed by association of each HERV with at least one CD4 or CD8 T cell signature.
[0070] In one embodiment, the association of HERVs with a cytotoxic T cell response is assessed by determining the association of each HERV with a transcriptome signature associated with at least one CD4 or CD8 T cell phenotype. In one embodiment, this step enables selection of HERVs associated with transcripts that indicate the presence of cells with a CD4 or CD8 T cell phenotype in a tumor sample.
[0071] Examples of methods for determining the phenotype of CD4 or CD8 T cells are well known to those skilled in the art, and include, for example, the Xcell method (D. Aran et al., xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017)) and MCP counter.
[0072] As used herein, Xcell is a gene signature-based method that performs cell type enrichment analysis based on gene expression data of 64 immune and stromal cell types. The xCell signature was validated by extensive computer simulation and cell counting immunophenotyping. The xCell R package for generating cell type scores and the R scripts for developing xCell are available at https: / / github.com / dviraran / xCell and deposited to Zenodo (assigned DOI http: / / doi.org / 10.5281 / zenodo.1004662).
[0073] In one embodiment, the characteristics used to determine the phenotype of a CD4 or CD8 T cell are based on characteristics of an Xcell.
[0074] In one embodiment, the features for determining the CD4 T cell phenotype, in particular the CD4 memory T cell phenotype, include or consist of the following genes: CD6, CD28, GPR183, EIF3E, ITK, PKP4, PREPL, DNAJA2, PTGES3, CD2AP and ICOS.
[0075] In one embodiment, the signature for determining a CD4 T cell phenotype, in particular a CD4 naive T cell phenotype, comprises or consists of the following genes: CD27, CLC, CTSW, DNAJB1, RBL2, HAUS3, ANKRD55, ZNF394, and CHMP7.
[0076] In one embodiment, the signature for determining the phenotype of a CD4 T cell comprises or consists of the following genes: APBB1, CD28, CTLA4, ITK, PLCL1, SNPH, PPWD1, PHF3, ICOS, TRAT1, RAPGEF6, NOL9, and CHMP7.
[0077] In one embodiment, the characteristics used to determine the CD4 T cell phenotype, in particular the CD4 central memory T cell phenotype (CD4Tcm), include or consist of the following genes: CCR4, CCR8, CTLA4, DAB1, ERN1, GPR15, DNAJB1, KRT1, POU6F1, TPO, TRADD, DLEC1, ICOS, TRAT1, FXYD7, FBXL8, SIRPG, ANKRD55 and OBSCN.
[0078] In one embodiment, the features for determining the CD4 T cell phenotype, in particular the CD4 effector memory T cell phenotype (CD4Tem), include or consist of the following genes: RPN2, SLAMF1, SPTAN1, TRADD, MYO16, MCF2L2, ESYT1, TRAPPC2L, ARHGAP15 and RIC8A.
[0079] In one embodiment, the features for determining the CD8 T cell phenotype (particularly the CD8 naive T cell phenotype) include or consist of the following genes: CD8A, CD8B, EEF1D, GPR15, MYL1, NDUFA4, NDUFS5, PSG11, SKI, SON, HIST1H3A, BUD31, GPR52, ZNHIT3, CGRRF1, RRP8, NGDN, C19orf53, SETD2, MED31, SS18L2, CDK5RAP1, DDX24, PCIF1, MS4A5, HAUS3, LIN28A and TNKS2.
[0080] In one embodiment, the signature for determining the phenotype of a CD8 T cell comprises or consists of the following genes: CASP8, CD8A, CD8B, GZMK, PTGDR, SLC1A7, TSPAN32, KLRG1, NPRL2, GIMAP4, CRTAM, and ZNF611.
[0081] In one embodiment, the features for determining the CD8 T cell phenotype, in particular the CD8 central memory T cell phenotype (CD8Tcm), include or consist of the following genes: CASP8, CD27, TNFSF8, GZMK, NCK1, GPR171, CRTAM, PARP11 and TMEM30B.
[0082] In one embodiment, the features for determining the CD8 T cell phenotype, in particular the CD8 effector memory T cell phenotype (CD8Tem), include or consist of the following genes: DHX8, GZMH, GZMK, LAG3, ZAP70, COLQ, RGS9, CXCR6, PVRIG and PYHIN1.
[0083] In one embodiment, the characteristics used to determine the phenotype of a CD4 or CD8 T cell are based on characteristics of an MCP counter.
[0084] In one embodiment, the signature for determining the phenotype of a CD4 or CD8 T cell comprises or consists of the following genes: CD28, CD3D, CD3G, CD5, CD6, CHRM3-AS2, CTLA4, FLT3LG, ICOS, MAL, MGC40069, PBX4, SIRPG, THEMIS, TNFRSF25, TRAT1, CD8B, CD8A, EOMES, FGFBP2, GNLY, KLRC3, KLRC4, KLRD1, BANK1, CD19, CD22, CD79A, CR2, FCRL2, IGKC, MS4A1, PAX5, CD160, KIR2DL1, KIR2DL3, KIR2DL4, KIR3DL1, KIR3DS 1. NCR1, PTGDR, SH2D1B, ADAP2, CSF1R, FPR3, KYNU, PLA2G7, RASSF4, TFEC, CD1A, CD1B, CD1E, CLEC10A, CL IC2, WFDC21P, CA4, CEACAM3, CXCR1, CXCR2, CYP4F3, FCGR3B, HAL, KCNJ15, MEGF9, SLC25A37, STEAP4, TEC PR2, TLE3, TNFRSF10C, VNN3, ACVRL1, APLN, BCL6B, BMP6, BMX, CDH5, CLEC14A, CXorf36, EDN1, ELTD1, EMC N, ESAM, ESM1, FAM124B, HECW2, HHIP, KDR, MMRN1, MMRN2, MYCT1, PALMD, PEAR1, PGF, PLXNA2, PTPRB, ROBO 4. SDPR, SHANK3, SHE, TEK, TIE1, VEPH1, VWF, COL1A1, COL3A1, COL6A1, COL6A2, DCN, GREM1, PAMR1 and TAGLN.
[0085] In one embodiment, the association of HERVs with a cytotoxic T cell response is assessed by determining the association of each HERV with a functional signature. In one embodiment, the functional signature is an interferon (IFN)-γ signature or cytolytic activity.
[0086] In one embodiment, the IFN-γ signature is based on genes upregulated in response to IFN-γ.In one embodiment, the association of HERVs with cytotoxic T cell responses is assessed by determining the association of each HERV with a transcriptome signature associated with an IFN-γ response.
[0087] In one embodiment, the IFN-γ signature is determined based on a database. For example, the IFN-γ signature database can be accessed through the Molecular Signature Database.
[0088] In one embodiment, the IFN-γ signature comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 40, 60, 80, 100, 120, 140, 160, 180, or 200 or all of the following genes: ADAR, APOL6, ARID5B, ARL4A, AUTS2, B2M, BANK1, BATF2, BPGM, BST2, BTG1, C1R, C1S, CASP1, CASP3, CASP4, CASP7, CASP8, CCL2, CCL5, CCL7, CD274, CD38, CD40, CD69, CD74, CD86, CDKN1A, CFB, CFH, CIITA, CMKLR1, CMPK2, C SF2RB, CXCL10, CXCL11, CXCL9, DDX58, DDX60, DHX58, EIF2AK2, EIF4E3, EPSTI1, FAS, FCGR1A, FGL2, FPR1, FTSJD2, GBP4, GBP6, GCH1, GPR18, GZMA, HERC6, HIF1A, H LA-A, HLA-B, HLA-DMA, HLA-DQA1, HLA-DRB1, HLA-G, ICAM1, IDO1, IF127, IFI30, IFI35, IFI44, IFI44L, IFIH1, IFIT1, IFIT2, IFIT3, IFITM2, IFITM3, IFNAR2, IL10RA, IL15, IL15RA, IL18BP, IL2RB, IL4R, IL6, IL7, IRF1, IRF2, IRF4, IRF5, IRF7, IRF8, IRF9, ISG15, ISG20, ISOC 1. ITGB7, JAK2, KLRK1, LAP3, LATS2, LCP2, LGALS3BP, LY6E, LYSMD2, 1-Mar, METTL7B, MT2A, MTHFD2, MVP, MX1, MX2, MYD88, NAMPT, NCOA3, NFKB1, NFKBIA, NLRC5, NMI, NOD1, NUP93, OAS2, OAS3, OASL, OGFR, P2RY14, PARP12, PARP14, P DE4B, PELI1, PFKP, PIM1, PLA2G4A, PLSCR1, PML, PNP, PNPT1, PRIC285, PSMA2, PSMA3, PSMB10, PSMB2, PSMB8, PSMB9 , PSME1, PSME2, PTGS2, PTPN1, PTPN2, PTPN6, RAPGEF6, RBCK1, RIPK1, RIPK2, RNF213, RNF31, RSAD2, RTP4, SAMD9L , SAMHD1, SECTM1, SELP, SERPING1, SLAMF7, SLC25A28, SOCS1, SOCS3, SOD2, SP110, SPPL2A, SRI, SSPN, ST3GAL5, ST 8SIA4, STAT1, STAT2, STAT3, STAT4, TAP1, TAPBP, TDRD7, TNFAIP2, TNFAIP3, TNFAIP6, TNFSF10, TOR1B, TRAFD1, TRIM14, TRIM21, TRIM25, TRIM26, TXNIP, UBE2L6, UPP1, USP18, VAMP5, VAMP8, VCAM1, WARS, XAF1, XCL1, ZBP1 and ZNFX1.
[0089] In one embodiment, the IFN-γ signature includes all of the genes described above. In one embodiment, the IFN-Y signature is HALLMARK_INTERFERON_GAMMA_RESPONSE (https: / / www.gseamsigdb.org / gsea / msigdb / cards / HALLMARK_INTERFERON_GAMMA_RESPO NSE.html).
[0090] In one embodiment, the IFN-γ signature is assessed by calculating an enrichment score for each sample of each cancer type based on an IFN-γ signature database.
[0091] In one embodiment, cytolytic activity is assessed by assessing the expression levels of granzyme-A (GZMA) and perforin (PRF1). In one embodiment, cytolytic activity is assessed by calculating the geometric mean of the expression levels of granzyme-A (GZMA) and perforin (PRF1).
[0092] In one embodiment, the expression levels of granzyme A (GZMA) and perforin (PRF1) are assessed at the transcriptome level. In one embodiment, the expression levels of granzyme A (GZMA) and perforin (PRF1) are assessed by RNA-seq.
[0093] As used herein, RNA-Seq (short for RNA sequencing) is a sequencing technology that uses next-generation sequencing (NGS) to reveal the presence and quantity of specific RNA in a biological sample at a specific moment in time.
[0094] RNA-seq data can be found in databases such as the NCBI Gene Expression Omnibus (GEO) portal.
[0095] In one embodiment, the expression levels of granzyme A (GZMA) and perforin (PRF1) are assessed at the proteomic level.
[0096] In one embodiment, the association of a HERV with a cytotoxic T cell response is assessed by the lack of expression of the HERV in normal purified T cells or NK cells. This step further enables the selection of HERVs that are expressed in tumor cells but not in T cells or NK cells.
[0097] Examples of HERVs expressed in T cells or NK cells are known to those skilled in the art and include, but are not limited to, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, and SEQ ID NO:41.
[0098] In one embodiment, the association of a HERV with a cytotoxic T cell response is assessed by assessing one, two or three of the parameters described above.
[0099] In one embodiment, the association of a HERV with a cytotoxic T cell response is assessed by: (i) association of each HERV with at least one CD4 or CD8 T cell signature, (ii) association of each HERV with an IFN-γ signature or a functional signature of cytolytic activity, and / or (iii) absence of expression of each HERV in normal purified T cells or NK cells.
[0100] In one embodiment, the association of HERV with one, two or three of the above parameters is assessed by a machine learning-based approach. In one embodiment, the association of each cancer type is tested independently using a machine learning-based approach. Machine learning used herein refers to artificial intelligence, wherein the algorithm builds a model based on training data.
[0101] In one embodiment, the association of HERV with one of the above parameters is assessed by regression, preferably L1 penalized regression (LASSO). Specifically, a model can be established for each cancer type, wherein each HERV with a positive coefficient in the model is considered to be associated with the parameter.
[0102] In one embodiment, the above method comprises the step of selecting T cell epitopes, in particular selecting shared T cell epitopes.
[0103] This step can in particular select epitopes that i) have common regions with known HERV proteins, thereby reducing the risk of selecting non-translated sequences; ii) are strong binders of MHC class I molecules, allowing them to be presented by MHC class I molecules. This step can also enable the selection of epitopes that iii) are one of the most shared epitopes in HERVs (e.g., HERVs associated with cancer).
[0104] In one embodiment, the method comprises the step of selecting a T cell epitope. In one embodiment, the step of selecting a T cell epitope comprises the step of determining a putative epitope.
[0105] In one embodiment, the step of selecting T cell epitopes comprises translating the HERV sequence into 1, 2, 3, 4, 5 or 6 possible frameworks and identifying open reading frames (ORFs) of at least 10, 11, 12, 13, 14, 15 or more amino acids to obtain putative epitopes.
[0106] In one embodiment, the step of selecting a T cell epitope comprises the step of predicting binding of the putative epitope to an MHC class I molecule.
[0107] Analysis tools for predicting sequence binding to MHC molecules are well known to those skilled in the art and include, for example, MHCflurry (TJO'Donnell et al., MHCflurry: Open-Source Class I MHC BindingAffinity Prediction. Cell Systems. 7, 129-132.e4 (2018)) or NetMCH I&II.
[0108] In one embodiment, the MCH class I molecule is an HLA molecule. In one embodiment, the MCH class I molecule is selected from the group comprising or consisting of: HLA-A, HLA-B and HLA-C molecules. In one embodiment, the MCH class I molecule is an HLA-A molecule, such as an HLA-A2 molecule.
[0109] In one embodiment, only T cell epitopes are selected that are predicted to be able to bind to MHC class I molecules. In one embodiment, an epitope is selected if its sequence is predicted to be a strong binder of MCH class I molecules as defined above.
[0110] In one embodiment, the step of selecting T cell epitopes comprises the step of aligning the epitopes with sequences of known HERV proteins to reduce the risk of selecting non-translated sequences.
[0111] In one embodiment, the HERV protein is an envelope (Env) protein. In one embodiment, the HERV protein is a group-specific antigen (Gag) protein. In one embodiment, the HERV protein is a polymerase (Pol). In one embodiment, the HERV protein is a protease (Pro). In one embodiment, the HERV protein is a Rec protein. In one embodiment, the HERV protein is an accessory protein.
[0112] In one embodiment, the HERV protein is a HERV-K / HML-2 protein. In one embodiment, the HERV protein is a HERV-K / HML-2 Gag protein. In one embodiment, the HERV protein is a HERV-K / HML-2 Pol protein.
[0113] Examples of HERV proteins include, but are not limited to, HERV-K10 Gag protein (SEQ ID NO: 20), HERV-K113 Gag protein (SEQ ID NO: 21), HERV-K21 Gag protein (SEQ ID NO: 22), HERV-K113 Pol protein (SEQ ID NO: 23), HERV-K9 Pol protein (SEQ ID NO: 24), HERV-K6 Pol protein (SEQ ID NO: 25), and HERV-K113 Env protein (SEQ ID NO: 26).
[0114] SEQ ID NO: 20
[0115]
[0116]
[0117] SEQ ID NO: 21
[0118]
[0119] SEQ ID NO: 22
[0120]
[0121] SEQ ID NO: 23
[0122]
[0123]
[0124] SEQ ID NO: 24
[0125]
[0126] SEQ ID NO: 25
[0127]
[0128] SEQ ID NO: 26
[0129]
[0130]
[0131] In one embodiment, if the sequence of the epi-position has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or higher identity with at least one HERV protein as defined above, the epi-position is selected. In one embodiment, if the sequence has at least 90% identity with at least one HERV protein as defined above, the sequence is selected.
[0132] In one embodiment, an epitope is selected if its sequence is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical to a HERV protein as defined above, and / or if the epitope is predicted to bind to an MHC class I molecule as described above.
[0133] In one embodiment, the method comprises a step of selecting an epitope from the most common epitopes in the HERV identified in one of the steps above. This step is particularly capable of selecting an epitope from the most common epitopes in HERVs (e.g., HERVs associated with cancer).
[0134] The steps may result in selecting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more epitopes among the most shared epitopes among the HERVs (eg, HERVs associated with cancer) identified in one of the previously described steps.
[0135] In one embodiment, the above method comprises a step of evaluating the expression of the epitope identified by one of the above steps in the tumor sample at the protein or peptide level. Said step can in particular confirm that the selected epitope is translated or expressed in the tumor sample.
[0136] In one embodiment, said expression of epitopes at the protein or peptide level is assessed in silico by using one or more proteomic databases.
[0137] Proteome databases can be obtained from tandem mass spectrometry (MS / MS) data. As used herein, tandem mass spectrometry (TANDEM MS), also known as MS / MS, refers to a mass spectrometry technique that uses two or more mass analyzers. When two tandem mass spectrometers are used, precursor ions are mass selected by the first mass analyzer and then focused into a collision region where they are then fragmented into product ions and then characterized by the second mass analyzer.
[0138] Analysis tools for evaluating the expression of proteins or peptides in databases are well known to those skilled in the art, including, for example, pepquery (B. Wen et al., PepQuery enables fast, accurate, and convenient proteomic validation of novel genomic alterations. Genome Res. 29, 485-493 (2019)).
[0139] In one embodiment, said expression of the epitope at the protein or peptide level is assessed in vitro by immunopeptidomic analysis.Immunopeptidomic analysis is able to assess the presence of epitopes associated with HLA molecules from tumors.
[0140] In one embodiment, an epitope is selected if it shows evidence of translation in a tumor sample, and / or evidence of translation in a tumor sample and association with an HLA molecule.
[0141] In one embodiment, the method as described above comprises the following steps:
[0142] (a) identifying HERVs associated with cancer, preferably associated with at least one cancer, and
[0143] (b) selecting T cell epitopes in the HERV identified in the previous step, and
[0144] The method further comprises at least one, preferably two, of the following steps:
[0145] (i) selecting a HERV associated with a cytotoxic T cell response from among the cancer-associated HERVs identified in step (a), said step being between step (a) and step (b), and / or
[0146] (ii) evaluating the expression of the HERV-derived T-cell epitope identified in step (b) at the protein or peptide level in the tumor sample, said step being subsequent to step (b).
[0147] In one embodiment, steps (a) and (b) and steps (i) and / or (ii) are in silico steps. In one embodiment, step (ii) is an in vitro step.
[0148] In one embodiment, step (a) comprises the steps of identifying and selecting HERVs associated with cancer, preferably associated with at least one cancer.
[0149] In one embodiment, step (b) comprises the step of selecting a shared T cell epitope.
[0150] In one embodiment, the method as described above comprises the following steps:
[0151] (a) identifying HERVs associated with cancer, preferably associated with at least one cancer, and
[0152] (b) selecting T cell epitopes in the HERV identified in the previous step, and
[0153] The method further comprises at least one, preferably two, of the following steps:
[0154] (i) selecting a HERV associated with a cytotoxic T cell response from among the cancer-associated HERVs identified in step (a), said step being between step (a) and step (b), and / or
[0155] (ii) evaluating the expression of the HERV-derived T-cell epitope identified in step (b) at the protein or peptide level in the tumor sample, said step being subsequent to step (b),
[0156] Wherein steps (a), (b), (i) and (ii) are performed in a computer.
[0157] Therefore, in one embodiment, the computer method as described above comprises the following steps:
[0158] (a) identifying HERVs associated with cancer, preferably associated with at least one cancer, and
[0159] (b) selecting T cell epitopes in the HERV identified in the previous step, and
[0160] The method further comprises at least one, preferably two, of the following steps:
[0161] (i) selecting a HERV associated with a cytotoxic T cell response from among the cancer-associated HERVs identified in step (a), said step being between step (a) and step (b), and / or
[0162] (ii) evaluating the expression of the HERV-derived T-cell epitope identified in step (b) at the protein or peptide level in the tumor sample, said step being subsequent to step (b).
[0163] In one embodiment, the method further comprises, after step (b) or before step (ii), a step of selecting epitopes from the epitopes with the highest commonality among the HERVs associated with cancer identified in step (a).
[0164] In one embodiment, the computer method as described above comprises the following steps:
[0165] (a) identifying a HERV associated with cancer, preferably associated with at least one cancer,
[0166] (b) selecting T cell epitopes in the cancer-associated HERV identified in step (a), and
[0167] (c) evaluating the expression of the HERV-derived T cell epitope identified in step (b) in the tumor sample at the protein or peptide level.
[0168] In one embodiment, the computer method as described above comprises the following steps:
[0169] (a) identifying a HERV associated with cancer, preferably associated with at least one cancer,
[0170] (b) selecting a HERV associated with a cytotoxic T cell response from among the cancer-associated HERVs identified in step (a),
[0171] (c) selecting T cell epitopes in the HERV identified in step (b), and
[0172] (d) evaluating the expression of the HERV-derived T cell epitope identified in step (c) in the tumor sample at the protein or peptide level.
[0173] In one embodiment, the computer method as described above comprises the following steps:
[0174] (a) identifying a HERV associated with cancer, preferably associated with at least one cancer,
[0175] (b) selecting T cell epitopes in the cancer-associated HERV identified in step (a),
[0176] (c) selecting an epitope from the epitopes with the highest commonality among the cancer-associated HERVs identified in step (a), and
[0177] (d) evaluating the expression of the HERV-derived T cell epitope identified in step (c) in the tumor sample at the protein or peptide level.
[0178] In one embodiment, the above computer method comprises the following steps:
[0179] (a) identifying a HERV associated with cancer, preferably associated with at least one cancer,
[0180] (b) selecting a HERV associated with a cytotoxic T cell response from among the cancer-associated HERVs identified in step (a),
[0181] (c) selecting T cell epitopes in the HERV identified in step (b),
[0182] (d) selecting an epitope from the epitopes with the highest commonality among the cancer-associated HERVs identified in step (a), and
[0183] (e) evaluating the expression of the HERV-derived T cell epitope identified in step (d) in the tumor sample at the protein or peptide level.
[0184] In one embodiment, the computer method as described above comprises the following steps:
[0185] (a) identifying a HERV associated with cancer, preferably associated with at least one cancer,
[0186] (b) selecting a HERV associated with a cytotoxic T cell response from among the cancer-associated HERVs identified in step (a), and
[0187] (c) selecting T cell epitopes in the cancer-associated HERV identified in step (b).
[0188] In one embodiment, the computer method as described above comprises the following steps:
[0189] (a) identifying a HERV associated with cancer, preferably associated with at least one cancer,
[0190] (b) selecting a HERV associated with a cytotoxic T cell response from among the cancer-associated HERVs identified in step (a),
[0191] (c) selecting T cell epitopes in the cancer-associated HERV identified in step (b), and
[0192] (d) selecting an epitope from the epitopes with the highest commonality among the cancer-associated HERVs identified in step (a).
[0193] In one embodiment, the steps are as described above.
[0194] In one embodiment, the above computer method comprises the following steps:
[0195] (a) identifying a HERV associated with cancer, preferably associated with at least one cancer,
[0196] (b) selecting a HERV associated with a cytotoxic T cell response from among the cancer-associated HERVs identified in step (a),
[0197] wherein the association of HERVs with cytotoxic T cell responses is assessed by: (i) association of each HERV with at least one CD4 or CD8 T cell signature, (ii) association of each HERV with an interferon (IFN)-γ signature or a functional signature of cytolytic activity, and / or (iii) absence of expression of each HERV in normal purified T cells or NK cells,
[0198] (c) selecting T cell epitopes in the HERV identified in step (b),
[0199] The selection of T cell epitopes includes the following steps:
[0200] - identification of putative epitopes,
[0201] - Prediction of binding of putative epitopes to MHC class I molecules,
[0202] - optionally, aligning the epitope with the sequence of known HERV proteins,
[0203] (d) optionally, selecting epitopes among the epitopes that are most commonly shared among cancer-associated HERVs, and
[0204] (e) Optionally, assessing the expression of the HERV-derived T-cell epitope identified in step (c) or (d) in the tumor sample at the protein or peptide level.
[0205] In one embodiment, the above method comprises the following steps:
[0206] (a) identifying HERVs associated with cancer, preferably associated with at least one cancer, and
[0207] (b) selecting T cell epitopes in the HERV identified in the previous step, and
[0208] The method further comprises at least one, preferably two, of the following steps:
[0209] (i) selecting a HERV associated with a cytotoxic T cell response from among the cancer-associated HERVs identified in step (a), said step being between step (a) and step (b), and / or
[0210] (ii) evaluating the expression of the HERV-derived T-cell epitope identified in step (b) at the protein or peptide level in the tumor sample, said step being subsequent to step (b),
[0211] Steps (a), (b) and (i) are performed on a computer, and step (ii) is performed in vitro.
[0212] In one embodiment, step (a) comprises the steps of identifying and selecting HERVs associated with cancer, preferably associated with at least one cancer.
[0213] In one embodiment, step (b) comprises the step of selecting a shared T cell epitope.
[0214] In one embodiment, the method further comprises, after step (b) or before step (ii), a step of selecting epitopes from the epitopes with the highest commonality among the cancer-associated HERVs identified in step (a).
[0215] In one embodiment, the above method comprises the following steps:
[0216] (a) identifying a HERV associated with cancer, preferably associated with at least one cancer,
[0217] (b) selecting T cell epitopes in the cancer-associated HERV identified in step (a), and
[0218] (c) evaluating the expression of the HERV-derived T cell epitope identified in step (b) in the tumor sample at the protein or peptide level,
[0219] Steps (a) and (b) are performed in a computer, and step (c) is performed in vitro.
[0220] In one embodiment, the method as described above comprises the following steps:
[0221] (a) identifying a HERV associated with cancer, preferably associated with at least one cancer,
[0222] (b) selecting a HERV associated with a cytotoxic T cell response from among the cancer-associated HERVs identified in step (a),
[0223] (c) selecting T cell epitopes in the HERV identified in step (b), and
[0224] (d) evaluating the expression of the HERV-derived T cell epitope identified in step (c) in the tumor sample at the protein or peptide level,
[0225] Steps (a), (b) and (c) are performed in a computer, and step (d) is performed in vitro.
[0226] In one embodiment, the above method comprises the following steps:
[0227] (a) identifying a HERV associated with cancer, preferably associated with at least one cancer,
[0228] (b) selecting T cell epitopes in the cancer-associated HERV identified in step (a),
[0229] (c) selecting an epitope from the epitopes with the highest commonality among the cancer-associated HERVs identified in step (a), and
[0230] (d) evaluating the expression of the HERV-derived T cell epitope identified in step (c) in the tumor sample at the protein or peptide level,
[0231] Steps (a), (b) and (c) are performed in a computer, and step (d) is performed in vitro.
[0232] In one embodiment, the above method comprises the following steps:
[0233] (a) identifying a HERV associated with cancer, preferably associated with at least one cancer,
[0234] (b) selecting a HERV associated with a cytotoxic T cell response from among the cancer-associated HERVs identified in step (a),
[0235] (c) selecting T cell epitopes in the HERV identified in step (b),
[0236] (d) selecting an epitope from the epitopes with the highest commonality among the cancer-associated HERVs identified in step (a), and
[0237] (e) evaluating the expression of the HERV-derived T cell epitope identified in step (d) in the tumor sample at the protein or peptide level,
[0238] Steps (a), (b), (c) and (d) are performed in a computer, and step (e) is performed in vitro.
[0239] In one embodiment, the steps are as described above.
[0240] In one embodiment, the above method comprises the following steps:
[0241] (a) identifying a HERV associated with cancer, preferably associated with at least one cancer,
[0242] (b) selecting a HERV associated with a cytotoxic T cell response from among the cancer-associated HERVs identified in step (a),
[0243] The association of HERVs with cytotoxic T cell responses was assessed by: (i) association of each HERV with at least one CD4 or CD8 T cell signature, (ii) association of each HERV with an interferon (IFN)-γ signature or a functional signature of cytolytic activity, and / or (iii) lack of expression of each HERV in normal purified T cells or NK cells.
[0244] (c) selecting T cell epitopes in the HERV identified in step (b),
[0245] The selection of T cell epitopes includes the following steps:
[0246] - identification of putative epitopes,
[0247] - Prediction of binding of putative epitopes to MHC class I molecules,
[0248] - optionally, aligning the epitope with the sequence of known HERV proteins,
[0249] (d) optionally, selecting epitopes among the epitopes that are most commonly shared among cancer-associated HERVs, and
[0250] (e) optionally, evaluating the expression of the HERV-derived T-cell epitope identified in step (c) or (d) in the tumor sample at the protein or peptide level,
[0251] Steps (a), (b), (c) and (d) are performed in a computer, and step (e) is performed in vitro.
[0252] In one embodiment, when steps (d) and (e) are present, they are performed in parallel. In one embodiment, when there is a step of aligning the epitope with the sequence of a known HERV protein and steps (d) and / or (e), they are performed in parallel.
[0253] In one embodiment, the method further comprises the step of aligning the selected epitope with the human proteome. This step can in particular confirm that the selected epitope does not match any self-protein.
[0254] In one embodiment, when the step of aligning the selected epitope with the human proteome and the step of aligning the epitope with the sequence of known HERV proteins, step (d) and / or step (e) are present, they are performed in parallel.
[0255] In one embodiment, the above method is combined with in vitro validation of the selected epitope. Specifically, the above method can be combined with one or more steps described below.
[0256] In one embodiment, the in vitro validation comprises the step of assessing the induction of a T cell response.
[0257] In one embodiment, the induction of a T cell response is assessed by measuring the induction of CD8+ T cells specific for a selected epitope. Examples of methods for assessing CD8+ T cell induction include, for example, in vitro priming assays using selected epitopes (eg, see the Examples section).
[0258] In one embodiment, the induction of a T cell response is assessed by measuring the production of IFN-γ or granzyme B in the presence of cells stimulated with the epitope (e.g., see the Examples section). Examples of methods for measuring IFN-γ or granzyme B production include, for example, flow cytometry or fluorospot assays.
[0259] In one embodiment, induction of a T cell response is assessed by measuring a degranulation marker (eg, CD107a) (eg, see the Examples section).
[0260] In one embodiment, the in vitro validation comprises a step of assessing the affinity of CD8+ T cells specific for the selected epitope to the MCH molecule. Examples of methods for assessing such affinity include, but are not limited to, 3D modeling (eg, see the Examples section).
[0261] In one embodiment, the in vitro validation comprises a step of evaluating the functionality of CD8+ T cells specific for the selected epitope. Examples of methods for measuring CD8+ T cell functionality include, but are not limited to, immune cell killing assays and analysis of morphological manifestations of T cell activation by microscopy (e.g., see the Examples section).
[0262] In one embodiment, the in vitro validation comprises the step of assessing the presence of T cells specific for the selected epitope in tumor tissue of a subject suffering from cancer (eg, see the Examples section). The tumor tissue may be obtained by biopsy.
[0263] The present invention also relates to a peptide comprising or consisting of an epitope identified by the above method.
[0264] The present invention relates to a peptide comprising or consisting of an epitope having a sequence selected from the group consisting of KLLGDINWI (SEQ ID NO: 1), FIFTLIAVI (SEQ ID NO: 2), RMLTDLRAV (SEQ ID NO: 3), FLSLYFVSV (SEQ ID NO: 4), TLIAVIMGL (SEQ ID NO: 5), YLDQIATLI (SEQ ID NO: 6), FLQAEVANA (SEQ ID NO: 7), WMGDRLMSL (SEQ ID NO: 8), ALHSSVQSV (SEQ ID NO: 9), ILTEVLKGV (SEQ ID NO: 10), LMAQAITGV (SEQ ID NO: 11), RLSYVHVTV (SEQ ID NO: 12), VLQDFDQPI (SEQ ID NO: 13), ALMIVSMVV (SEQ ID NO: 14), MLLAALMIV (SEQ ID NO: 15), YIDDILCAA (SEQ ID NO: 16), YIIHYIDDI (SEQ ID NO: 17), NO: 17), YIWCPTWRL (SEQ ID NO: 18) and YIWCPTWSL (SEQ ID NO: 19). The present invention relates to a peptide comprising or consisting of KLLGDINWI (SEQ ID NO: 1), FIFTLIAVI (SEQ ID NO: 2), RMLTDLRAV (SEQ ID NO: 3), FLSLYFVSV (SEQ ID NO: 4), TLIAVIMGL (SEQ ID NO: 5), YLDQIATLI (SEQ ID NO: 6), FLQAEVANA (SEQ ID NO: 7), WMGDRLMSL (SEQ ID NO: 8), ALHSSVQSV (SEQ ID NO: 9), ILTEVLKGV (SEQ ID NO: 10), LMAQAITGV (SEQ ID NO: 11), RLSYVHVTV (SEQ ID NO: 12), VLQDFDQPI (SEQ D NO: 13), ALMIVSMVV (SEQ D NO: 14), MLLAALMIV (SEQ ID NO: 15), YIDDILCAA (SEQ ID NO: 16), YIIHYIDDI (SEQ ID NO: 17), YIWCPTWRL (SEQ ID NO: 18), NO: 18) and YIWCPTWSL (SEQ ID NO: 19).
[0265] In one embodiment, the peptide comprises or consists of an epitope having a sequence selected from the group comprising or consisting of: RMLTDLRAV (SEQ ID NO: 3), ALHSSVQSV (SEQ ID NO: 9), LMAQAITGV (SEQ D NO: 11), VLQDFDQPI (SEQ ID NO: 13), ALMIVSMVV (SEQ ID NO: 14), MLLAALMIV (SEQ ID NO: 15), YIDDILCAA (SEQ ID NO: 16). In one embodiment, the peptide comprises or consists of a sequence selected from the group comprising or consisting of: RMLTDLRAV (SEQ ID NO: 3), ALHSSVQSV (SEQ ID NO: 9), LMAQAITGV (SEQ ID NO: 11), VLQDFDQPI (SEQ ID NO: 13), ALMIVSMVV (SEQ ID NO: 14), MLLAALMIV (SEQ ID NO: 15), YIDDILCAA (SEQ ID NO: 16).
[0266] In one embodiment, the peptide comprises or consists of an epitope having a sequence selected from the group comprising or consisting of: RMLTDLRAV (SEQ ID NO: 3), LMAQAITGV (SEQ D NO: 11), VLQDFDQPI (SEQ D NO: 13), ALMIVSMVV (SEQ ID NO: 14), MLLAALMIV (SEQ ID NO: 15), YIDDILCAA (SEQ ID NO: 16). In one embodiment, the peptide comprises or consists of a sequence selected from the group comprising or consisting of: RMLTDLRAV (SEQ ID NO: 3), LMAQAITGV (SEQ ID NO: 11), VLQDFDQPI (SEQ ID NO: 13), ALMIVSMVV (SEQ ID NO: 14), MLLAALMIV (SEQ ID NO: 15), YIDDILCAA (SEQ ID NO: 16).
[0267] In one embodiment, the peptide comprises or consists of an epitope having a sequence selected from the group comprising or consisting of: RMLTDLRAV (SEQ ID NO: 3), LMAQAITGV (SEQ ID NO: 11), VLQDFDQPI (SEQ ID NO: 13), ALMIVSMVV (SEQ ID NO: 14), YIDDILCAA (SEQ ID NO: 16). In one embodiment, the peptide comprises or consists of a sequence selected from the group comprising or consisting of: RMLTDLRAV (SEQ ID NO: 3), LMAQAITGV (SEQ ID NO: 11), VLQDFDQPI (SEQ ID NO: 13), ALMIVSMVV (SEQ ID NO: 14), YIDDILCAA (SEQ ID NO: 16).
[0268] In one embodiment, the peptide comprises or consists of an epitope of the sequence KLLGDINWI (SEQ ID NO: 1). In one embodiment, the peptide comprises or consists of an epitope of the sequence FIFTLIAVI (SEQ ID N: 2). In one embodiment, the peptide comprises or consists of an epitope of the sequence RMLTDLRAV (SEQ ID NO: 3). In one embodiment, the peptide comprises or consists of an epitope of the sequence FLSLYFVSV (SEQ ID NO: 4). In one embodiment, the peptide comprises or consists of an epitope of the sequence TLIAVIMGL (SEQ ID NO: 5). In one embodiment, the peptide comprises or consists of an epitope of the sequence YLDQIATLI (SEQ ID NO: 6). In one embodiment, the peptide comprises or consists of an epitope of the sequence FLQAEVANA (SEQ ID NO: 7). In one embodiment, the peptide comprises or consists of an epitope of the sequence WMGDRLMSL (SEQ ID NO: 8). In one embodiment, the peptide comprises or consists of an epitope of the sequence ALHSSVQSV (SEQ ID NO: 9). In one embodiment, the peptide comprises or consists of an epitope of the sequence ILTEVLKGV (SEQ ID NO: 10). In one embodiment, the peptide comprises or consists of an epitope of the sequence LMAQAITGV (SEQ ID NO: 11). In one embodiment, the peptide comprises or consists of an epitope of the sequence RLSYVHVTV (SEQ ID NO: 12). In one embodiment, the peptide comprises or consists of an epitope of the sequence VLQDFDQPI (SEQ ID NO: 13). In one embodiment, the peptide comprises or consists of an epitope of the sequence ALMIVSMVV (SEQ ID NO: 14). In one embodiment, the peptide comprises or consists of an epitope of the sequence MLLAALMIV (SEQ ID NO: 15). In one embodiment, the peptide comprises or consists of an epitope of the sequence YIDDILCAA (SEQ ID NO: 16). In one embodiment, the peptide comprises or consists of an epitope of the sequence YIIHYIDDI (SEQ ID NO: 17). In one embodiment, the peptide comprises or consists of an epitope of the sequence YIWCPTWRL (SEQ ID NO: 18). In one embodiment, the peptide comprises or consists of an epitope of the sequence YIWCPTWSL (SEQ ID NO: 19).
[0269] In one embodiment, the peptide comprises or consists of KLLGDINWI (SEQ ID NO: 1). In one embodiment, the peptide comprises or consists of FIFTLIAVI (SEQ ID N: 2). In one embodiment, the peptide comprises or consists of RMLTDLRAV (SEQ ID NO: 3). In one embodiment, the peptide comprises or consists of FLSLYFVSV (SEQ ID NO: 4). In one embodiment, the peptide comprises or consists of TLIAVIMGL (SEQ ID NO: 5). In one embodiment, the peptide comprises or consists of YLDQIATLI (SEQ ID NO: 6). In one embodiment, the peptide comprises or consists of FLQAEVANA (SEQ ID NO: 7). In one embodiment, the peptide comprises or consists of WMGDRLMSL (SEQ ID NO: 8). In one embodiment, the peptide comprises or consists of ALHSSVQSV (SEQ ID NO: 9). In one embodiment, the peptide comprises or consists of ILTEVLKGV (SEQ ID NO: 10). In one embodiment, the peptide comprises or consists of LMAQAITGV (SEQ ID NO: 11). In one embodiment, the peptide comprises or consists of RLSYVHVTV (SEQ ID NO: 12). In one embodiment, the peptide comprises or consists of VLQDFDQPI (SEQ ID NO: 13). In one embodiment, the peptide comprises or consists of ALMIVSMVV (SEQ ID NO: 14). In one embodiment, the peptide comprises or consists of MLLAALMIV (SEQ ID NO: 15). In one embodiment, the peptide comprises or consists of YIDDILCAA (SEQ ID NO: 16). In one embodiment, the peptide comprises or consists of YIIHYIDDI (SEQ ID NO: 17). In one embodiment, the peptide comprises or consists of YIWCPTWRL (SEQ ID NO: 18). In one embodiment, the peptide comprises or consists of YIWCPTWSL (SEQ ID NO: 19).
[0270] The peptides can be prepared by any technique known to those skilled in the art, including expression of proteins, polypeptides or peptides by standard molecular biology techniques, isolation of proteins or peptides from natural sources, or chemical synthesis of proteins or peptides. Synthetic peptides are generally up to about 35 residues, which is about the upper limit of the length of an automatic peptide synthesizer (e.g., provided by Applied Biosystems (Foster City, Calif.)). Longer peptides can also be prepared, for example, by recombinant methods.
[0271] The present invention also relates to an expression vector for inducing the expression of one or more of the above-mentioned peptides. The present invention also relates to an expression vector comprising a nucleic acid sequence encoding one or more of the above-mentioned peptides.
[0272] The vector can be, in particular, an RNA vector, a DNA vector or a plasmid, a viral vector or a bacterial vector. The expression cassette may or may not be integrated into the host cell genome, depending on the nature of the vector, which is well known to those skilled in the art. The expression vector or expression cassette may also contain elements necessary for in vivo expression of the nucleic acid (polynucleotide) in a subject. For example, this may consist of a start codon (ATG), a stop codon and a promoter, as well as polyadenylation sequences of certain vectors (e.g., plasmids and viral vectors other than poxviruses). The ATG may be placed at the 5′ position of the reading frame, and the stop codon may be placed at the 3′ position. It is known that other elements that may control expression may be present, such as enhancer sequences, stabilizing sequences, and signal sequences that allow secretion of the peptide.
[0273] Regarding RNA vectors, the vectors can use, for example, non-replicating mRNA or virus-derived self-amplifying RNA. Conventional mRNA-based vectors can encode target peptides and can include 5' and 3' untranslated regions (UTRs). Self-amplifying RNA can encode not only target peptides, but also viral replication machinery, thereby achieving intracellular RNA amplification and large amounts of protein expression.
[0274] Examples of viral vectors include, but are not limited to, lentiviruses and retroviruses.
[0275] In one embodiment, the method for obtaining a peptide as described above comprises:
[0276] - Introducing the vector as described above into competent host cells in vitro or ex vivo;
[0277] - Cultivating the host cells transformed with the above expression vector in vitro or in vitro under conditions suitable for peptide expression;
[0278] - optionally, selecting cells that express and / or secrete said peptide; and
[0279] - Recovering the expressed peptide.
[0280] The present invention also relates to cytotoxic T lymphocytes (CTL) of a subject treated with one or more of the above-mentioned peptides.
[0281] The present invention also relates to cytotoxic T lymphocytes (CTL) of a subject treated with one or more of the expression vectors described above.
[0282] The present invention also relates to a T cell receptor (TCR) that recognizes the above peptides.
[0283] The present invention also relates to engineered T cells expressing TCRs that recognize the above peptides.
[0284] Methods for preparing these T cells are known to those skilled in the art. They may be as follows: (i) TCR α and β chains are isolated from T cells that recognize the above peptides and inserted into vectors; (ii) T cells isolated from the peripheral blood of patients or donors are modified with such vectors to encode the desired TCR α β sequence; (iii) these modified T cells are then expanded in vitro to obtain sufficient numbers for treatment and administered to patients. It is worth noting that the TCR sequence can be modified to optimize TCR affinity.
[0285] The present invention also relates to one or more peptides, one or more expression vectors, one or more CTLs, or one or more engineered T cells as described above, for use as a vaccine.
[0286] The present invention also relates to one or more peptides, one or more expression vectors, one or more CTLs, or one or more engineered T cells as described above for use as a medicament.
[0287] The present invention also relates to one or more peptides, one or more expression vectors, one or more CTLs, or one or more engineered T cells as described above for use in treating or preventing cancer in a subject in need thereof.
[0288] The present invention also relates to the use of one or more peptides, one or more expression vectors, one or more CTLs, or one or more engineered T cells as described above in the preparation of a medicament for treating or preventing cancer in a subject in need thereof.
[0289] The present invention also relates to a method of treating or preventing cancer in a subject in need thereof, wherein the method comprises administering to the subject one or more peptides, one or more expression vectors, one or more CTLs, or one or more engineered T cells as described above.
[0290] In one embodiment, the cancer is selected from the group comprising or consisting of breast cancer (including triple negative breast cancer (TNBC)), ovarian cancer, melanoma, sarcoma, teratocarcinoma, bladder cancer, lung cancer (including non-small cell lung cancer and small cell lung cancer), head and neck cancer, colorectal cancer, glioblastoma, leukemia, lymphoma and other solid tumors and hematological malignancies.
[0291] In one embodiment, the cancer is selected from the group comprising or consisting of breast cancer (including triple negative breast cancer (TNBC)), ovarian cancer, melanoma, sarcoma, lung cancer (including non-small cell lung cancer and small cell lung cancer), head and neck cancer, glioblastoma, leukemia, lymphoma and other solid tumors and hematological malignancies.
[0292] In one embodiment, the cancer is breast cancer, preferably TNBC.
[0293] In one embodiment, one or more peptides, one or more expression vectors, one or more CTLs or one or more engineered T cells as described above induce an immune response, such as a T cell response, preferably an immune response against a tumor-associated epitope.
[0294] The skilled artisan will be aware of various assays for determining whether an immune response to a tumor-associated epitope has been generated. Various B lymphocyte and T lymphocyte assays are well known, such as ELISA, cytotoxic T lymphocyte (CTL) assays (e.g., chromium release assays), proliferation assays using peripheral blood lymphocytes (PBL), tetramer assays, and cytokine production assays.
[0295] Therefore, the present invention also relates to a method of inducing an immune response in a subject in need thereof, wherein the method comprises administering one or more peptides, one or more expression vectors, one or more CTLs, or one or more engineered T cells as described above to the subject.
[0296] In one embodiment, one or more peptides, one or more expression vectors, one or more CTLs, or one or more engineered T cells as described above are administered in a therapeutically effective amount.
[0297] However, it should be understood that the total daily usage of one or more peptides, one or more expression vectors, one or more CTLs, or one or more engineered T cells as described above will be determined by the attending physician within the scope of sound medical judgment.
[0298] The specific dosage for any particular subject will depend on a variety of factors, including the symptoms being treated and the severity of the symptoms; the activity of the specific compound employed; the specific composition employed, the age, weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or concomitantly with the specific compound employed; and like factors well known in the medical arts.
[0299] In order to be used for applying to a subject, the one or more peptides, one or more expression vectors, one or more CTLs or one or more engineered T cells will be formulated for use to a subject. One or more peptides, one or more expression vectors, one or more CTLs or one or more engineered T cells as described above can be administered parenterally, by inhalation spray, rectal, nasal or by implanted reservoirs. The term used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
[0300] BRIEF DESCRIPTION OF THE DRAWINGS
[0301] FIG1 is a combination of a chart and a histogram showing pancancer identification of HERVs associated with CTL responses. FIG1A : Venn diagram showing the total number of HERVs overexpressed in tumors compared to their normal counterparts (peritumoral tissue), and the total number of HERVs overexpressed in normal peritumoral tissues compared to their tumor counterparts. HERVs that are overexpressed in at least one tumor and never overexpressed in any peritumoral tissue are considered to be associated with cancer. FIG1B : Venn diagram showing the selection criteria for annotating HERVs as associated with CTL responses (cyt-HERVs). Each HERV must be associated with phenotypic (CD8 or CD4 T cell characteristics) and functional (cytolytic activity (granzyme B and perforin 1) or IFN-γ characteristics) criteria (A and B) and not overexpressed in normal purified T / NK cells (A and B but not C). FIG1C : Venn diagram of cancer-associated HERVs associated with the CTL response criteria defined in A. A total of 192 HERVs were annotated as cyt-HERVs. Figure 1D : The proportion of cancer-associated HERVs annotated as cyt-HERVs in each cancer subtype. Cyt-HERVs are represented in light grey. CTL: cytotoxic T cell response, Cyt-HERV: HERVs associated with CTL response in cancer, TNBC: triple-negative breast cancer.
[0302] FIG2 is a combination of a histogram, a schematic diagram, and a table showing the selection of consensus HLA-A2 epitopes derived from Gag and Pol HERV-K / HML-2. Figure 2A: Flowchart for peptide selection from cyt-HERV sequences. Fig. 2B: Bar graph of the top 25 most shared peptides predicted as strong HLA-A*02 binders among 192 cyt-HERVs. Selected peptides (P1 to P6) are marked with asterisks. Fig. 2C: Characteristics of 6 selected HLA-A2 epitopes. 9-mer peptides were selected based on their predicted HLA-A*02 affinity (considering strong binders with percentile rank ≤ 0.5) and the number of HERVs containing their sequences.
[0303] Figure 3 is a combination of a graph and two histograms showing that consensus CD8+ T cell epitopes derived from conserved Gag and Pol HERV-K / HML-2 motifs are expressed in TNBC. Figure 3A: Venn diagram of the total number of cyt-HERVs overexpressed in each breast cancer subtype in the TCGA database. Figure 3B: Average expression of 54 cyt-HERVs overexpressed in the TCGA basal subtype, the independent database of Varley et al., and medullary thymic epithelial cells (mTEC). Figure 3C : The expression of 18 CAH-containing peptides in breast cancer basal cell lines (Hs578t and MDA-MB-231) and luminal A cell lines (MCF7 and T47D) was analyzed by Riboseq.
[0304] Figure 4 is a combination of a schematic diagram and a graph showing that HERV-derived epitopes induce polyfunctional CD8+ T cell responses. Figure 4A: Schematic diagram of the in vitro priming protocol. Figure 4B: Summary of results obtained using PBMCs from 11 HLA-A2 positive HDs (HD1 to HD11, one donor per row). Figure 4C : Graphs of IFN-γ (left), IFN-γ and TNF-α (middle), or IFN-γ and CD107a (right) staining, gated for CD8+ T cells. PBMCs were stimulated with peptide (here P6, top row), no peptide (middle row), or CMVpp65 peptide (bottom row).
[0305] Figure 5 is a combination of tables and graphs showing visualization of CDR loops and interactions of CDR loops with peptides. Figure 5A: Production frequencies of TCRα and TCRβ CDR3 sequences specific to the first few clones for each peptide (P1, P2, P4, P6) and corresponding resolved V, D and J alleles. Figure 5B: Predicted binding affinity (predicted Δg) is expressed in kcal / mol. Reported is the average value. Asterisks indicate significant statistical tests at the 5% level (Welch two-sample t-test). Figure 5C: Graphs of modeled HERV-specific TCR-pMHC and reference TCR-pMHC complexes available in the Protein Data Bank and obtained from crystallographic data are ranked according to their predicted binding affinity. CDR: complementary determining region, TCR: T cell receptor; MHC: major histocompatibility complex; pMHC: peptide-MHC, TRA: α chain of TCR; TRB: β chain of TCR.
[0306] Figure 6 is a combination of graphs showing that HERV-specific T cell clones are functional, recognize and kill tumor cells. Figure 6A: Functional avidity of CD8+ T cell clones calculated by nonlinear fitting of normalized IFN-γ production. N9-V1 and -2: CMV-specific T cell clones (see Methods). The EC50 of each clone is indicated by the dotted interpolation on the X-axis. Figure 6B: Quantification of cell death, expressed as the increase in fluorescence intensity from baseline (Y-axis) over time (hours, X-axis). Figure 6C : Specific tumor cell lysis at 48 h. The average percentage of three technical replicates for each condition is plotted (data are representative of at least 2 independent experiments).
[0307] Figure 7 is a combination of a diagram and a photograph showing that HERV-specific T cells are present among tumor-infiltrating T cells. Fig. 7A : Overall survival according to 18-HERV score in TCGA HLA-A2 TNBC patients (n=65). Patients were divided into three groups according to the score percentile: high expression (n=22); medium expression (n=21); low expression (n=22). Figure 7B : 60X images of TNBC organoids co-cultured with CMV, P1 or P6-specific CD8+ T cell clones (from top to bottom) acquired using Nanolive technology at different time points. White arrows indicate T cells. Example
[0308] The present invention is further illustrated by the following examples.
[0309] Materials and methods
[0310] Dataset
[0311] For RNA-seq data, raw fastq files can be accessed from the NCBI Gene Expression Omnibus (GEO) portal, the independent breast cancer dataset of Varley et al. (KEVarley et al., Recurrent read-through fusion transcripts in breast cancer. Breast Cancer Res. Treat. 146, 287-297 (2014)) has the accession number GSE58135, the sorted PBMC dataset (MRCorces et al., Lineage-specific and single-cell chromatin accessibility charts human hematopoiesisand leukemia evolution. Nature Genetics. 48, 1193-1203 (2016)) has the accession number GSE74246, and six mTEC samples (J.-D. Larouche et al., Widespread and tissue-specific expression of endogenous retroelements in human somatic tissues. Genome Med.12, 1-16 (2020)) with access numbers GSE127825 and GSE127826. TCGA Pan-Cancer raw fastq files were accessed from the Genomic Data Commons (GDC) portal (https: / / portal.gdc.cancer.gov / ). Cell line data were accessed from the Broad Institute Cancer Cell Line Encyclopedia (CCLE) portal (https: / / portals.broadinstitute.org / ccle).
[0312] HERV expression quantification
[0313] HERV expression was assessed using the HervQuant process (CC Smith et al., Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. Journal of Clinical Investigation. 128, 4804-4820 (2018)). In brief, RNAseq reads were mapped to the hg19 reference transcriptome (LVargiu et al., Classification and characterization of human endogenous retroviruses; mosaic forms are common. Retrovirology. 13, 7 (2016)) using STAR v2.7.3a (A. Dobin et al., STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 29, 15-21 (2013)) using annotations of 3,173 HERV sequences. As in the original publication, multiple positioning ≤10 and mismatch ≤7 were allowed. BAM output was filtered for reads mapped to HERV sequences using SAMtools v1.4 (H. Li et al., 1000 Genome Project Data Processing Subgroup, The Sequence Alignment / Mapformat and SAMtools. Bioinformatics. 25, 2078-2079 (2009)), and then quantified using Salmon v0.7.2 (R. Patro et al., Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference. Nat Methods. 14, 417-419 (2017)). The raw counts were normalized to counts per million total reads and then log2+1 transformed.
[0314] Quality Check / Sample Filtering
[0315] Including only primary solid tumor samples (TCGA code 01), 9,718 samples from 32 different cancer types were regrouped, of which 9,492 samples could be analyzed for HERV expression. Quality checks led to the complete removal of ESCA and STAD samples due to severely skewed HERV distribution, resulting in a final analysis of 8,893 samples from 29 different cancer types.
[0316] Immune signature and genetic alterations
[0317] Phenotypic immune signatures were calculated using the Xcell method (D. Aran, et al., xCell: digitally portraying the tissuecellular heterogeneity landscape. Genome Biol. 18, 220 (2017)). For TCGA Pan-Cancer samples, Xcell signatures were downloaded directly from the Xcell website (https: / / xcell.ucsf.edu / xCell_TCGA_RSEM.txt). For the GSM1401648 dataset, signatures were calculated for the entire dataset and then immune signatures were filtered. Interferon-γ (IFN-γ) signatures were calculated using single sample gene set variation analysis (GSVA) (S. et al., GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics. 14, 7 (2013)). The HALLMARK_INTERFERON_GAMMA_RESPONSE feature in the Molecular Signature Database (http: / / software.broadinstitute.org / gsea / msigdb / index.jsp) was used. The enrichment score for each sample of each cancer type was calculated. Cytolytic activity (CYT_score) was calculated as the geometric mean of granzyme B (GRZB) and perforin (PRF1) expression, as described previously (MS Rooney et al., Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 160, 48-61 (2015)). TCGA pan-cancer gene mutations come from Thorsson V. et al. (V. Thorsson et al., The Immune Landscape of Cancer. Immunity. 48, 812-830.e14 (2018)).
[0318] Cancer associations and cvt-HERV annotations
[0319] To define cancer specificity, HERV differential expression was performed on tumor samples and their corresponding normal peritumoral matching tissues. Only TCGA studies with at least 10 peritumoral samples were included (n = 14 different cancer types). HERV differential expression analysis was performed independently for each TCGA cancer type. After filtering out HERVs expressed more than 2 times in any normal tissue compared to its matched tumor, the remaining HERVs overexpressed more than 2 times in at least one cancer compared to its normal counterpart (peritumoral tissue) were considered to be associated with cancer.
[0320] To be annotated as potential immunogenicity, each cancer-associated HERV must be associated with at least one phenotypic (A) standard and a functional (B) standard, and not overexpressed (C) in T / NK cells. Phenotypic criteria include association with CD4 or CD8+ T cell features defined by Xcell methods. Functional criteria include association with IFN-γ or cytolytic activity, defined by the geometric mean value of granzyme-A (GZMA) and perforin (PRF1) expression. Normal PBMC expression (MRCorces et al., Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemiaevolution. Nature Genetics. 48, 1193-1203 (2016)) was assessed in an independent data set of sorted PBMC from healthy donors. HERV expression in T cells and NK cells is independently compared with HERV expression in the remaining PBMCs.
[0321] L1 Penalized Regression (LASSO)
[0322] Associations were calculated by Lasso regression using the glmnet and c060 packages (JH Friedman et al., Regularization Paths for Generalized Linear Models via CoordinateDescent. Journal of Statistical Software. 33, 1-22 (2010), M. Sill et al., c060: Extended Inference with Lasso and Elastic-Net Regularized Cox and Generalized Linear Models. Journal of Statistical Software. 62, 1-22 (2014)). Gaussian distributions were considered for CYT scores and IFN-γ features, and Poisson distributions were considered for Xcell features. HERVs were analyzed as log2 (CPM+1) without further standardization. For each cancer type, a model was established based on the best parameters found by 10-fold cross validation. Each HERV with a positive coefficient in the final model (based on the lambda parameter that minimizes the mean square error) was considered to be associated with the variable.
[0323] Epitope screening
[0324] Open reading frame (ORF) detection was performed using sixpack from EMBOSS v6.6.0.0 (F. Madeira et al., The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res. 47, W636-W641 (2019)). The detected ORFs of more than 10 amino acids were then aligned with known HML-2 (HERV-K) Gag, Pro, Pol, Env, Rec, and Np9 proteins referenced in UniProt (UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 47, D506-D515 (2019)). Blast with optimal parameters for retroviruses was used (character size = 3, composition-based statistics, no "low complexity region" filtering). Then, MHCflurry v1.3 (TJ O'Donnell et al., MHCflurry: Open-Source Class I MHCBinding Affinity Prediction. Cell Systems. 7, 129-132.e4 (2018)) was used to screen for conserved sequences with greater than 90% identity to Gag and Pol protein alignment and e-value <0.05 for predicted HLA-A*02 strong binders. Peptides ranked <= 0.5 percentile were considered strong binders. Before peptide synthesis and in vitro validation, the human proteome was downloaded from Uniprot (ID: UP000005640) to verify the missing matches.
[0325] Cumulative expression score
[0326] Referring to the method proposed by Xiao et al (Y. Xiao et al., A novel significance score for gene selection and ranking. Bioinformatics. 30, 801-807 (2014)), the π-value score for each HERV and each tissue comparison (TNBC relative to peritumoral tissue) was determined, expressed as the product of the log2 change fold of expression and the log10 of the inverse of the p value. The cumulative expression score was calculated by adding the π-values of all HERVs containing epitope sequences (including CAH and other HERVs).
[0327] Analysis of peptide histone proteomics datasets
[0328] The original MS / MS data set was downloaded from CPTAC (NJ Edwards et al., The CPTAC Data Portal: A Resource for Cancer Proteomics Research. J Proteome Res. 14, 2707-2713 (2015)) for breast cancer research (Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature. 490, 61-70 (2012); K. Krug et al., Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell. 183, 1436-1456.e31 (2020)). The exported MS / MS spectra were converted to MGF format using msconvert from proteowizard (R.Adusumilli, P.Mallick, Data Conversionwith ProteoWizard msConvert.Methods Mol Biol.1550,339-368(2017)). The peptide list was then analyzed using a standalone version of Pepquery (v.1.6.2.0) (B.Wen et al., PepQuery enables fast, accurate, and convenient proteomic validation of novel genomic alterations.Genome Res.29,485-493(2019)). The command line used was: java -Xmx10G -jar pepquery.jar -fixMod 6,62,108 -varMod 117 -maxVar 3 -c 1 -tol10 -tolu ppm -minScore 12 -e 1 -um -hc TRUE -n 1000 -itol 0.05 -m 1 cpu 12 -pep${peptides_list} -db${Reference_database} -ms${MS_database} -o${output_directory}. For the second dataset, the fixmod and varMod in the command line were adjusted as follows: -fixmod 6,103,157 -varMod 101,117.
[0329] Riboseq analysis
[0330] The ribosome profiling data were obtained from a previously published study (F. Loayza-Puch et al., Tumour-specific proline vulnerability uncovered by differential ribosome codon reading. Nature. 530, 490-494 (2016)). The original fastq files were preprocessed as described in the initial publication. In brief, the adapter sequence was trimmed from the raw data using cutadapt1.1 and parameters (--quality-base=33-O12-m20-q5) and mapped to our reference hg19-HERV transcriptome.
[0331] Statistical analysis
[0332] All analyses were performed using R statistical software version 3.6.0. HERV differential expression analysis was performed using DESEQ2 v1.24.0 (MI Love et al., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014)), and the apeg1m package was used to reduce the logarithmic fold change (A. Zhu et al., Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. Bioinformatics. 35, 2084-2092 (2019)).
[0333] Biological samples
[0334] Blood from healthy donors was obtained from the Etablissement du Sang" (Lyon). Fresh TNBC (n = 11) was provided by Centre Léon Bérard (CLB) (BB-0033-00050, CRB-CLB, Lyon, France; French protocol number: AC-2013-1871) after approval by the Institutional Review Board and Ethics Committee (L-06-36 and L-11-26) according to the Declaration of Helsinki and written informed consent from the patients.
[0335] Peptide synthesis
[0336] The peptides were synthesized by JPT Peptide Technologies (GE, EU) with a specification and purity of >90%. The lyophilized powder was resuspended in 1% DMSO distilled water.
[0337] Cell lines
[0338] MDA-MB-231 basal breast cancer epithelial cells were obtained from the American Type Culture Collection (ATCC catalog name: HTB-26) and cultured in 10% FBSDMEM (Gibco, FR, EU), 1% penicillin / streptomycin, 1% L-glutamine. HMEC primary cells were obtained from Promocell (GE, EU) and cultured in mammary epithelial growth medium (Promo Cell, GE, EU).
[0339] In vitro priming assay
[0340] PBMCs were obtained by Ficoll density gradient centrifugation (Eurobio, FR, EU). They were rapidly thawed at 37°C and washed thoroughly, then placed at room temperature or at 37°C overnight before assessing their viability. On day 0, 0.15 × 10 6 PBMC / well, culture using AIM V medium (Gibco, FR, EU) and enriched with 5 μg / mL R-848 (Resquimod), 10 μg / mL HMW poly-IC (all from Invivogen, FR, EU), 20 IU / mL IL-2 (PROLEUKINaldesleukine, Novartis Pharma, CH, EU) and 10 μg / mL target peptide. After 3, 6 and 10 days, replace 100 μL medium with enriched fresh medium (only IL-2 and peptide on the 6th day, only IL-2 on the 10th day), batch if necessary. Collect cells and count for analysis on the 12th day.
[0341] Feeding plan
[0342] CD8 + T cells were expanded on feeders containing 35 Gy irradiated allogeneic PBMC and B lymphoblastoid cell line in a 10:1 ratio. Feeder cells were seeded at a concentration of 0.10 x 106 cells per well in 96-well round-bottom plates in RPMI 5% human serum containing PHA-L 1.5 μg / mL (Merck KgAa, GE, EU) and IL-2 150 IU / mL (NovartisPharma, CH, EU). Up to 5 x 106 cells were added per well. 3 The cells were cultured for 14 days and the medium was replaced with fresh RPMI 5% human serum enriched with IL-2 when necessary. This process was repeated if necessary.
[0343] TCR immunosequencing
[0344] Using QIAGEN DNA Blood Micro kit (QIAGEN, GE, EU) from specific CD8 + DNA was extracted from T cells and corresponding bulk PBMCs and sent to Adaptive Biotechnologies (WA, US) for TCR investigation and in-depth analysis.
[0345] 3D model generation and refinement
[0346] For each T cell clone from previously published immunosequencing results, the complete TCR sequence of the alpha and beta chains was reconstructed (A. Gros et al., Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ 1ymphocytes. J Clin Invest. 129, 4992-5004 (2019)). For the variable domains, the TRA and TRB CDR3 nucleotide sequences were obtained from immunosequencing (Figure 5A), and the 5′ and 3′ ends of the TRAV and TRBV regions were obtained from the International Immunogenetics Information System (IMGT) online database. The human constant domains of TRA and TRB were added to the 3′ of the variable domain to reconstruct the full-length TCR. These full-length TCR sequences were submitted to the CBS TCRpMHCmodels-1.0 web server together with the MHC and peptide sequences, which was developed specifically for automatic structural modeling of TCR-pMHC complexes using template-based modeling (KK Jensen et al., TCRpMHCmodels: Structural modelling of TCR-pMHC class I complexes. Sci Rep. 9, 14530 (2019)). TCR residues were renumbered using a standardized procedure (KRAbhinandan, ACRMartin, Analysis and improvements to Kabat and structurally correct numbering ofantibody variable domains. Mol Immunol. 45, 3832-3839 (2008); MSKlausen et al., LYRA, a webserver for lymphocyte receptor structural modeling. Nucleic Acids Res. 43, W349-355 (2015)).The initial model generated by the web server was further refined in four rounds using a protocol adapted from Bobisse et al (S. Bobisse et al., Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-naive ovarian cancer. Nat Commun. 9, 1-10 (2018)). Briefly, CDR loops were refined in pairs using Modeller software version 9.25 (A. Fiser, A. Sali, Modeller: generation and refinement of homology-based protein structure models. Methods Enzymol. 374, 461-491 (2003); A. Sali, TL Blundell, Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 234, 779-815 (1993)): CDR loop α1 / α2 in round 1, α1 / α3 in round 2, β1 / β2 in round 3, and β1 / β3 in round 4. Only residues in the coiled conformation in the initial model were refined. In each round, 500 models were generated, and the best model based on Modeller's internal DOPE score was selected as input for the next round.
[0347] At the end of four rounds, a representative model was selected based on the consensus of unweighted contacts as follows: contacts between residues on the TCR-pMHC interface (defined as distances between heavy atoms less than 5 angstroms) were counted in the set of 4*25 models with the highest DOPE scores in each round of refinement. Then, among the 25 models with the highest DOPE scores in the last round, the model with the highest number of recurring contacts, called the unnormalized CONSRANK score (G. Launay et al., Evaluation of CONSRANK-Like Scoring Functions for Rescoring Ensembles of Protein-Protein Docking Poses. Front Mol Biosci. 7, 559005 (2020); R. Oliva et al., Ranking multiple docking solutions based on the conservation of inter-residue contacts. Proteins. 81, 1571-1584 (2013)), was selected as the representative model.
[0348] Quantitative insights into potential stabilizing interactions between TCR and pMHC were provided by the observed inter-residue contact frequencies in the 4*25 model sets with the best DOPE scores in each round of refinement.While the CDR1 and CDR3 loops of TCRα and TCRβ chains interact with both MHC and peptides, the CDR2 loop interacts primarily with MHC molecules.
[0349] 3D structural analysis
[0350] The structural similarity between representative models of different complexes was assessed by using RMSD between the backbone CDR loops calculated using UCSF Chimera (EF Pettersen et al., UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 25, 1605-1612 (2004)). As expected, the structural variability within the CDRβ3 loop was the highest. UCSF Chimera was also used to detect hydrogen bonds and hydrophobic contacts and structural visualization.
[0351] Binding affinity prediction
[0352] Binding affinities were predicted using the prodigy method (A. Vangone, A. M. Bonvin, Contacts-based prediction of binding affinity in protein-protein complexes. Elife. 4, e07454 (2015)), which uses a linear model based on the number and type of contacts at the interface. For each complex, instead of running predictions once on a representative model, we averaged the predictions of the 25 models with the best DOPE scores obtained in round 4 of the refinement protocol.
[0353] Fluorescent spots
[0354] PBMC or CD8 + After co-culture of T cells with T2 cells (with or without peptide pulse) at a ratio of 10:1 in AIM V medium (Gibco, FR, EU) at 37°C, 9% CO2 for 24 h, a two-color fluorescent spot assay using IFN-γAF488 and Grz-b CTL-red (CTL GmbH, CA, US) was performed according to the manufacturer's instructions. The revelation plate is read on the S6ULTIMATE UV image analyzer and used Analyze using analysis software.
[0355] Functional Avidity
[0356] Dextramer-isolated specific CD8 against selected peptides (P1, P2, P6) + T cells were used for functional avidity IFN-γ production testing by enzyme-linked immunosorbent assay (IFN-γ ELISA, Thermo Fisher scientific, FR, EU). Two CMV T cell clones specific for the immunodominant epitope N9V (NLVPMVATV) were used. N9V-1 corresponds to the pp65 dextramer-selected CD8 + T cells, N9V-2 were CD8 provided by Dr. Henri Vie + T cell cloning was performed by 10 -4 Up to 10 -9 M(log) limiting peptide dilution to assess specific CD8 + Functional avidity of T cell responses. After washing, peptide-pulsed T2 cells were incubated with specific CD8 +T cells were co-cultured in AIM-V medium (Gibco, FR, EU) supplemented with 5% human serum at a ratio of 1:1. After 18 hours, supernatants were collected and subjected to ELISA. The half-maximal cytokine response (EC 50 ) required peptide concentration (50% EC (EC) was determined using GraphPad Prism version 6.0 for Windows) 50 ) determination, R>0.98).
[0357] Epitope verification and quantification by MS
[0358] Epitope validation and quantification were performed by CompleteOmics Inc. (Maryland, USA) by MS according to a previously described method (J.Douglass et al.Bispecific antibodiestargeting mutant RAS neoantigens.Sci Immunol.6, eabd5515 (2021)) with further modifications. In brief, a total of 300 million cells were lysed, and the peptide-HLA complex was immunoprecipitated using a self-assembled Valid-NEO neoantigen enrichment column pre-loaded with anti-human HLA-A, B, C antibody clone W6 / 32 (Bio-X-Cell). After elution, dissociation, filtration, and cleaning up, the peptides were lyophilized and then further analyzed. The conversion parameters of each epitope peptide were checked and organized by the Valid-NEO method generator bioinformatics process to exclude ions that produce too much noise due to co-elution with impurities and to improve detectability by recursively optimizing important ions. Based on quantification using heavy isotope-labeled peptides, the absolute copy number of peptides presented on the cell surface was calculated. The MS data have been deposited via ProteomeXchange and are accessible via the identifier PASS01698.
[0359] Real-time imaging
[0360] Cells were seeded in DMEM (Gibco, FR, EU) medium, 10% SVF, 1% penicillin / streptomycin. For IncuCyte analysis, the medium was removed from the 96-well plate after the cells adhered overnight. Depending on the conditions, blocking HLA-A2 antibodies (GeneTex, clone BB7.2, GTX75806, CA, US) were added to AIM-V medium (Gibco, FR, EU) for 1 hour. T cells were then added in the presence of IncuCyte Cytotox dye (EssenBioscience, UK, EU) at an effector cell to target cell (E:T) ratio of 2:1 for cell death quantification. Real-time imaging was performed using Incucyte Zoom at 37°C 5% CO2 for 48 hours. Cell death was calculated as the total number of stained cells counted divided by the number of stained cells counted at baseline. Maximum killing was determined using DMSO. Specific lysis was calculated according to the following formula:
[0361] % specific lysis = (((HERV-specific T cell-induced target cell death-spontaneous target cell death)-(non-specific dextramer-negative T cell-induced target cell death-spontaneous target cell death)) / (DMSO-induced target cell death-spontaneous target cell death)) x 100
[0362] For Nanolive imaging, T cells were subsequently added at an E:T ratio of 10:1 and phase imaging was performed every minute using the Nanolive Microscope 3D Cell Explorer.
[0363] Tumor dilaceration: organoids and TIL expansion
[0364] The tumor tissue was cut into pieces of approximately 1 mm3 and lysed in RPMI enriched with 20% SVF using collagenase IV and DNAse. Tear The tumor lysate was centrifuged at 1500 rpm for 5 minutes and resuspended in RPMI enriched with 5% human serum. The cells were counted and 5×10 4 Cells were seeded at a density of 10 cells / well in a flat-bottom 96-well plate containing anti-CD3 and anti-CD28 Dynabeads (Dynabeads, Gibco, EU) and 100 IU / mL IL-2 at a beads to cell ratio of 1:4.
[0365] For organoids, a portion of the tumor lysate (3 to 10 million cells) was resuspended in 10 ml of Advanced DMEM / F12 medium. The cells were centrifuged at 500rcf for 10 seconds and then resuspended in complete medium. Depending on the number of cells at the beginning, this protocol was repeated 3 to 5 times to enrich the cell suspension of epithelial cells. These cells were then cultured according to the protocol previously described by Drehuis et al. (E.Driehuis et al., Establishment of patient-derived cancer organoids for drug-screening applications.Nature Protocols.15, 3380-3409 (2020)).
[0366] Multiparameter flow cytometry
[0367] T cells were counted and co-cultured with T2 cells (loaded or not with relevant peptides) at a ratio of 5:1. One hour later, CD107a antibody (BD, clone H4A3) was added to each well with Golgi plug (1 / 1000) (10 μg / mL, BD, FR, EU). After 5 hours, viability, surface and intracellular staining were performed. To assess CD8 + Cytokine expression in T cells was determined by intracellular staining using the FoxP3 fixation and permeabilization kit (Thermo Fisher scientific, LifeTechnologies, CA, US) according to the manufacturer’s instructions.
[0368] Dextramer staining was performed on PBMC after 12 days of culture (priming protocol) or TIL expanded for 14 days after tumor tearing. Cells were washed in 2mL washing buffer (PBS+2%FBS+2mM EDTA (Sigma Alderich, MI, US)) and stained with dextramer (Immudex ApS, DK, EU) at room temperature for 10 minutes, followed by viability and surface marker staining. Washed 2 times to avoid non-specific dextramer staining. CMV pp65NLVPMVATV was used as a positive control. For TIL analysis, dextramers compounded with non-natural unrelated peptides (ALIAPVHAV) were used as negative controls.
[0369] All samples were analyzed on an LSR-Fortessa (BD Biosciences, FR, EU) with settings kept constant throughout the study. Data analysis was performed using FlowJo software (Tree Star v10.4, NJ, USA).
[0370] result
[0371] Machine learning-based approach identifies HERVs associated with CTL responses
[0372] To optimize epitope detection, we developed a new pipeline for annotating HERVs. To this end, we reviewed multiple HERV databases and selected the most recent and complete reference of 3,173 HERVs, most of which contained complete proviral sequences and were therefore more likely to contain translated peptides. We used HervQuant to evaluate HERV expression in 8,893 primary tumor samples from 29 different cancer types from the Cancer Genome Atlas (TCGA) Pan-Cancer RNAseq database. We selected cancers with at least 10 available matched peritumoral samples (n = 14) to filter out HERVs that were highly expressed in tumors but not in normal tissues (cancer-associated HERVs or CAH). HERV differential expression analysis found 1,134 CAH candidates (Figure 1A). To reduce the number of candidates to be tested, we next applied a second filter to retain only HERVs associated with CTL responses in CAH (cyt-HERVs). Cyt-HERV annotation is based on two inclusion criteria, i.e. each HERV is associated with at least one CD4 or CD8 T cell phenotype (A) and function (B) feature, and an exclusion criterion, i.e. it is expressed by purified T cells or NK cells (C) (A and B rather than C) (Fig. 1B). In order to reduce the risk of false positive associations and control the high colinearity encountered by HERV expression, these associations are evaluated by L1 penalty regression (R.Tibshirani, Regression Shrinkage and Selection via the Lasso.Journal of the Royal Statistical Society.58,267-288 (1996)), to only retain the HERV highly associated with CTL response, control cancer subtype. Using a machine learning-based method, each cancer type is independently tested for relevance (see Methods section for details), and 192 cyt-HERVs (Fig. 1C) are finally identified. Subcancer analysis showed that colon adenocarcinoma (COAD), lung squamous cell carcinoma (LUSC), head and neck squamous cell carcinoma (HNSC), bladder urothelial carcinoma (BLCA), and lung adenocarcinoma (LUAD) were the top five cancers with the highest total number of cyt-HERVs ( Figure 1D ).
[0373] Overall, cyt-HERVs accounted for approximately 15% of total CAH, greatly reducing the number of potential candidates. Of the most shared cyt-HERVs, 11 were overexpressed in more than 10 different types of cancer, including 3 HERVs (herv_2256, herv_6069, and herv_4700) that have previously been reported to induce CD8+ T cell responses. Analysis of the average beta values of the 10 nearest surrounding probes from TCGA Illumina450k methylation data showed that more cyt-HERVs were significantly associated with local demethylation (n=37) compared with methylation (n=15), suggesting that these HERVs are under partial epigenetic control.
[0374] Selection of conserved Gag and Pol HERV-K / HML-2 motifs in cyt-HERVs identifies shared CD8+ T cells Epitope
[0375] We next assessed the presence of shared T-cell epitopes between these cyt-HERVs, focusing on HLA-A2, the most common HLA class I allele. We translated our 192 cyt-HERV sequences into 6 possible frameworks and retained predicted open reading frames (ORFs) of at least 10 amino acids. To reduce the number of false positives (untranslated sequences), we aligned these ORFs with known HERV-K / HML-2 Gag and Pol proteins referenced in UniProt and retained only ORFs with 90% homology to known existing HML-2 proteins. This conservative approach identified 57 HML-2HLA-A*0201 epitope candidates from 27 different ORFs ( Figure 2A), of which herv_2410 and herv_6069 showed the largest number of conserved HML-2-derived ORFs. To better understand the distribution of these epitopes, we relocated each peptide in all CAHs. Figure 2B shows the top 25 most shared epitopes. 13 unique epitopes were present in at least 10 different HERVs (Figure 2B). For further biological validation and immunological assays, we selected 6 most shared epitope candidates: 3 from Gag (P1, P2 and P4) and 3 from Pol (P3, P5 and P6) (Figure 2C). Analysis of mass spectrometry (MS) data from TCGA and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) showed evidence of translation of the P1, P2, P3, P5 and P6 peptides. P4 was also selected because it has been described in HLA-I eluted peptides from tumors (patent WO2019 / 162110A1). Importantly, alignment with the human proteome revealed that the sequences of these epitope candidates did not match any self-protein sequences. Notably, these HLA-A2 epitopes were not predicted to be strong binders of the other most common HLA-A and B alleles.
[0376] Triple-negative breast cancer (TNBC) is characterized by numerous cyt-HERVs containing shared HERV epitopes
[0377] We focused here on breast cancer due to the well-characterized expression of HERVs in TNBC and the availability of RNA sequencing (RNAseq) databases containing normal samples. HERV differential expression analysis found that a total of 497 CAHs were expressed in different breast cancer subtypes, of which 91 were annotated as cyt-HERVs. Fifty-four of these 91 cyt-HERVs were expressed in the basal subtype (Figure 3A). The average expression of these 54 cyt-HERVs was significantly higher in TNBC and ER+ samples compared with peritumoral or normal breast tissue from independent datasets (Figure 3B). We confirmed that these 54 cyt-HERVs were highly expressed in breast cancer cell lines sequenced in the study of Varley et al. and cell lines from the Broad Institute Cancer Cell Line Encyclopedia. The top 25 most common epitope candidates among all CAHs expressed in the basal subtype included 6 previously identified peptides P1-P6.
[0378] Next, we selected HERVs containing sequences of six previously identified epitope candidates, P1-P6, among CAHs expressed in the basal subtype. 18 different CAHs contained at least one of the six peptides in their ORFs (Table 1).
[0379] Table 1
[0380] herv_id P1 P2 P3 P4 P5 P6 herv_2953 x herv_4833 x x x herv_3232 x herv_4873 x x x x herv_6069 x x x x x x herv_2025 x x x x x x herv_6079 x x x x x herv_2704 x x x x x x herv_1741 x x x herv_3192 x x x x herv_3288 x herv_2794 x herv_2288 x herv_2582 x x x x x x herv_4679 x he, v_2476 x herv_4695 x x x x x x herv_3652 x x x x x
[0381] Genomic mapping of the corresponding loci revealed the dispersed locations of these 18 HERVs on the chromosomes. To quantify the differential expression of HERVs containing the epitope in TNBC and normal tissues (represented here by each available peritumoral sample), we used a π-value score that takes into account both statistical significance (given by p-value) and biological significance (represented by fold change). The cumulative expression score for each epitope was then calculated by summing the π-values of all HERVs containing its sequence. In most cases this score ranged from 10 to 200, confirming that the HERVs containing the epitope were significantly overexpressed in TNBC relative to each normal sample evaluated. Finally, analysis of ribosome profiling (riboseq) data from previously published studies showed that the 18 peptide-containing CAHs had evidence of translation in four different breast tumor cell lines, including two basal subtypes and two luminal A subtypes ( Figure 3C ).
[0382] Overall, our bioinformatic approach enabled us to select a limited number of HERV-derived T-cell epitopes that are specifically overexpressed by tumor cells and most likely to be immunogenic among a large number of HERV candidates.
[0383] HERV-derived epitopes induce strong and multifunctional T cell responses
[0384] We then assessed the ability of the selected epitope candidates to induce effective T cell responses. The HLA-A2 affinity of the six selected peptides was first confirmed on purified HLA-A*02:01 molecules using an in vitro binding assay. To assess the immunogenicity of these six peptides, we developed an optimized in vitro priming assay that was performed on peripheral blood mononuclear cells (PBMCs) from HLA-A2-positive donors (see Figure 4A and Methods section for details). Dextramer-based quantification of peptide-specific CD8+ T cells showed the presence of specific T cells for all peptides and that there were differences between donors (Figure 4B). P1 appeared to be the most immunogenic peptide, with significant T cell responses in 9 / 11 donors, followed by P4 (7 / 10), P6 (4 / 9), and P2 (3 / 11) (Figure 4B). The immunogenicity of these peptides was further confirmed by classical assays using monocyte-derived dendritic cells (MoDCs) prepared from five HLA-A2-positive healthy donors. Flow cytometric analysis showed that when peptide-stimulated PBMCs were co-cultured with T2 cells pulsed with relevant epitopes, CD8+ T cell IFN-γ was produced. Notably, P1 also induced the highest IFN-γ response compared to the other peptides. Consistent with bioinformatics predictions, no specific T cell induction was observed using PBMCs from HLA-A2 negative donors (n=5).
[0385] Based on these results, we selected P1, P2, P4, and P6 for further experiments. When stimulated PBMCs were co-cultured with peptide-pulsed T2 cells, polyfunctional IFN-γ+ TNF-α+ specific CD8+ T cell responses were observed, associated with the presence of the degranulation marker CD107a ( Figure 4C ). Fluorescent spot assays under the same co-culture conditions confirmed the secretion of IFN-γ and granzyme B in the presence of double-positive cells.
[0386] Characterization of epitope-specific CD8+ T cell clones with high predicted affinity T cell receptors (TCRs)
[0387] P1, P2, P4, and P6-specific CD8+ T cells were sorted by flow cytometry using dextramer staining and expanded on feeder cells (see Methods). After one (P1) or two steps (P2, P4, and P6) of selection and expansion, more than 90% (90-99%) of CD8+ T cells were dextramer positive. TCRβ immunosequencing confirmed the presence of dominant clones with unique Vβ rearrangements, accounting for 90.8%, 90.7%, 99.6%, and 76% of P1, P2, P4, and P6 expanded T cells, respectively (Figure 5A). It is worth noting that the V / D / J recombinant sequences of the TCRβ that characterize these clones were not present in the T cell population before peptide stimulation (threshold sensitivity: 3x10-6). The TCRα chain was also sequenced, and the presence of unique master clones in P1, P4, and P6 was confirmed, enabling TCR pairing and modeling. Since 2 major Vα rearrangements were obtained for P2, the major rearrangement occurring at a frequency of 60% was used for TCR modeling.
[0388] By considering the 3D model of the TCR-peptide-MHC (pMHC) complex, the affinity of the T cell clones specific to peptides P1, P2, P4 and P6 was characterized (see the method section). The stability of the macromolecular complex is attributed to the favorable interactions formed at the interface, such as hydrogen bonds, salt bridges and hydrophobic interactions. These interactions involve specific side chains of the peptides exposed at the TCR-pMHC interface. In the TCR P1 complex, the Phe1, Phe4 and Trp8 side chains of the peptide form multiple hydrophobic interactions, and the backbone atoms of Phe 4 and Ile 9 participate in H-bonds. In the TCR P2 complex, multiple hydrophobic interactions are mediated by peptide residues Pro4, Tyr5 and Trp7. In TCR P4, peptide residues Ile5, Ile7 and Leu8 form multiple hydrophobic interactions, while Tyr1 and Lys6 side chains and Phe4 and Leu8 backbone atoms participate in H-bonds. In TCR P6, Tyr1, Ser4, Asn5, Leu6, and Phe7 form multiple hydrophobic interactions, while the Ser4 / Leu6 / Ser8 backbone and Tyr1 / Ser4 / Asn5 / Ser8 side chains form eight H-bonds.
[0389] Overall, analysis of the predicted 3D models showed that the TCR-pMHC complex is stabilized by multiple favorable non-covalent interactions, supporting the conclusion that the identified TCRs form stable complexes with peptides presented by HLA-A2 molecules after clonal expansion of HERV-specific T cells. To gain further insight, we submitted the 3D models to binding affinity predictions (Figure 5B). Compared to reference TCR-pMHC complexes available in the Protein Data Bank and obtained from crystallographic data, the predicted affinities of the identified TCRs match those of clinically relevant TCRs, such as those targeting MAGE-A3, NY-ESO-1, MART-1, HTLV, or CMV (Figure 5C). Therefore, it is predicted that the identified HERV-specific TCRs will stably interact with their respective pMHC complexes, suggesting high-affinity TCRs.
[0390] High-avidity HERV-specific T cell clones recognize and kill tumor cells
[0391] The functionality of the sorted and expanded epitope-specific CD8+ T cells was verified by fluorescent spot assay using peptide-pulsed T2 cells. Subsequently, functional avidity was assessed by loading T2 cells with decreasing concentrations of the relevant peptide (ranging from 10-4 to 10-9 M) and measuring the minimum peptide concentration required to elicit an IFN-γ response in 50% of the cells (defined as the half-maximal effective concentration, or EC50). For P1, P2, and P6-specific T cells, the EC50 values were estimated to be 6.6x10 -7 M, 1.9x10 -6 M and 6.8x10 -6 M, compared with neo-epitope-specific T cell clones (28) and CMV-specific T cells (1.2 × 10 for N9V-1 and N9V-2, respectively). -6 and 1.9x10 -6 ) are in the same order of magnitude (Figure 6A).
[0392] Next, we evaluated the ability of these HERV epitope-specific CD8+ T cells to recognize and kill tumor cells. We selected the HLA-A2-positive MDA-MB-231 basal BRCA tumor cell line as a target candidate, which has been previously shown to express HERV containing epitope sequences ( Figure 3C ). To provide evidence that the epitopes are indeed presented on the cell surface, an MS-based approach was used to analyze peptides eluted from HLA molecules. The P1 and P6 epitopes were clearly detected by MS. Based on comparison with heavy isotope-labeled controls, we estimated that there were 1.8 copies of the P1-HLA complex on the surface of MDA-MB-231 cells.
[0393] Tumor cells were co-cultured with epitope-specific T cells or dextramer-negative CD8+ T cell fractions (negative controls) sorted and expanded under the same conditions. Flow cytometric analysis showed that approximately 25% of epitope-specific T cells contacted with MDA-MB-231 produced IFN-γ, a significant increase (>6-fold) compared to the background observed with nonspecific T cells. This IFN-γ production was inhibited by an HLA-A2 blocking monoclonal antibody, indicating that the T cell clones specifically recognized tumor cells in an HLA-A2-restricted manner.
[0394] To monitor tumor cell death in real time, we performed an immune cell killing assay using IncuCyte technology. T cell clones induced significant HLA-A2-restricted killing of MDA-MB-231 cells, as shown by the increase in the amount of Cytotox fluorescent reagent on target cells over time. In contrast, the dextramer-negative fraction of T cells did not induce significant cell death of MDA-MB-231 cells (with or without peptide pulse) (Figure 6B). Specific lysis (effector to target ratio E:T = 2:1) was calculated based on the quantification of target cell death after 48 hours minus the background of isogenic reactions (assessed by target cell death induced by the corresponding dextramer-negative T cell fraction) (see Methods section). Particularly high specific lysis of tumor cells was achieved using P1 and P2-specific T cells (35% and 44%, respectively), while lysis was more modest with P6-specific T cells (15%). When target tumor cells were pulsed with relevant epitopes, specific lysis was further improved, reaching 55%, 80% and even 95% for P1, P2 and P6 specific T cells, respectively. It is noteworthy that epitope-specific T cell clones did not kill HLA-A2 positive human mammary epithelial cells (HMEC) ( Figure 6C ). These results were further validated by 3D microscopy Nanolive technology, showing morphological signs of specific T cell activation associated with killing of most tumor cells after 4.5 hours (E:T=10:1). Similarly, no cell death was observed when specific T cells were co-cultured with HMEC and when MDA-MB-231 cells were co-cultured with nonspecific T cells. Similar results were obtained using the TNBC HLA-A2-positive cell line HCC1599 as a target. In summary, these data indicate that the selected epitopes trigger high-avidity CD8+ T cell clones that selectively recognize and kill HERV-expressing tumor cells.
[0395] HERV-specific T cells are present among tumor-infiltrating T cells
[0396] To test our hypothesis that adaptive immune responses against HERVs may exist in cancer patients, we evaluated the presence of HERV epitope-specific T cells in polyclonally expanded tumor-infiltrating lymphocytes (TILs) from TNBC HLA-A2 patients who did not receive any peptide-specific stimulation by dextramer staining. HERV-specific TILs were observed against at least one epitope in 7 of 11 tumor samples analyzed, with variability in epitope specificity and frequency across patients. P1, P4, and P6 were the most frequently recognized peptides, identified based on dextramers in 4 / 11, 4 / 11, and 5 / 11 cases, respectively.
[0397] These results prompted us to investigate the potential association between the prognosis of TNBC patients and the expression of 18 CAHs containing these HLA-A2 epitopes. We established a score based on the average expression of these 18 HERVs in HLA-A2 patients with basal breast cancer in the TCGA cohort. Interestingly, HLA-A2-positive patients with high or intermediate 18-HERV scores had significantly better overall survival than those with low scores (P = 0.0066) ( Fig. 7A ). This prognostic effect was not observed in the overall population.
[0398] Finally, we evaluated the antitumor activity of HERV-specific T cells against primary tumor cells using organoids derived from patient 8's tumor (see Methods section). RNAseq analysis confirmed the expression of 18 epitope-containing CAHs in early and late passages. In 3D microscopy Nanolive experiments, tumor organoids were co-cultured with P1, P6, or CMV-specific CD8+ T cell clones (E:T = 10:1). Although no T cell activation was observed in CMV-specific T cells, P1- and P6-specific T cells showed signs of active proliferation associated with organoid lysis ( Figure 7B ).
[0399] Together, these final results suggest that HERV-specific T cells are induced during tumor development and may participate in antitumor immune responses.
Claims
1. A method for identifying human endogenous retrovirus (HERV)-derived T-cell epitopes associated with at least one cancer, wherein the method comprises the following steps: (a) identifying a HERV associated with at least one cancer, and (b) selecting T cell epitopes among the HERVs identified in the previous step, and The method further comprises at least one, preferably two, of the following steps: (i) selecting a HERV associated with a cytotoxic T cell response from the cancer-associated HERVs identified in step (a), said step being located between step (a) and step (b), and / or (ii) evaluating the expression of the HERV-derived T cell epitope identified in step (b) at the protein or peptide level in the tumor sample, said step being after step (b), Preferably, steps (a), (b), (i) and (ii) are in silico steps, or steps (a), (b) and (i) are in silico steps and step (ii) is an in vitro step.
2. The method of claim 1, wherein step (a) comprises the step of comparing HERV expression in tumor and normal samples.
3. The method according to any one of claims 1 or 2, wherein step (b) comprises the step of aligning the sequence of the HERV identified in the previous step with the HERV protein.
4. The method of claim 3, wherein step (b) further comprises the step of predicting binding of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity to a HERV protein to an MHC class I molecule.
5. The method according to any one of claims 1 to 4, wherein the association of the cancer-associated HERV with the cytotoxic T cell response in step (i) is assessed by the association of each HERV with at least one CD4 or CD8 T cell signature, the association of each HERV with a functional signature being an interferon (IFN)-γ signature or cytolytic activity, and the lack of expression of each HERV in normal purified T cells or NK cells, preferably wherein the association is assessed by a machine learning-based method.
6. The method according to any one of claims 1 to 5, wherein the method further comprises, after step (b) or before step (ii), a step of selecting an epitope from the most common epitopes among the cancer-associated HERVs identified in step (a).
7. The method according to any one of claims 1 to 6, wherein the method further comprises, after step (b) or after step (ii), a step of comparing HERV-derived T cell epitopes with the human proteome.
8. A peptide comprising or consisting of an epitope identified by the method of any one of claims 1 to 7.
9. A peptide comprising or consisting of an epitope having a sequence selected from the group comprising or consisting of: RMLTDLRAV (SEQ ID NO: 3), LMAQAITGV (SEQ ID NO: 11), VLQDFDQPI (SEQ ID NO: 13), MLLAALMIV (SEQ ID NO: 15) and YIDDILCAA (SEQ ID NO: 16).
10. An expression vector which induces expression of one or more peptides according to claim 8 or claim 9.
11. Cytotoxic T lymphocytes of a subject treated with one or more peptides of claim 8 or 9 or one or more expression vectors of claim 10.
12. An engineered T cell expressing a T cell receptor that recognizes the peptide of claim 8 or claim 9.
13. One or more peptides of claim 8 or claim 9, one or more expression vectors of claim 10, one or more cytotoxic T lymphocytes of claim 11, or one or more engineered T cells of claim 12, for use as a vaccine or a medicine.
14. One or more peptides of claim 8 or 9, one or more expression vectors of claim 10, one or more cytotoxic T lymphocytes of claim 11, or one or more engineered T cells of claim 12, for use in preventing or treating cancer in a subject in need thereof.
15. The one or more peptides, one or more expression vectors, one or more cytotoxic T lymphocytes or one or more engineered T cells for use according to claim 14, wherein the cancer is selected from the group comprising or consisting of breast cancer including triple-negative breast cancer, ovarian cancer, melanoma, sarcoma, teratocarcinoma, bladder cancer, lung cancer including non-small cell lung cancer and small cell lung cancer, head and neck cancer, colorectal cancer, glioblastoma, leukemia, lymphoma and other solid tumors and hematological malignancies.
